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Abstract
Personalized medicine has been utilized in all stages of cancer care in recent years,
including the prevention, diagnosis, treatment and follow-up. Since prevention and early
intervention are particularly crucial in reducing cancer mortalities, personalizing the
corresponding strategies and decisions so as to provide the most appropriate or optimal medical
services for different patients can greatly improve the current cancer control practices. This
dissertation research performs an in-depth exploration of personalized decision modeling of
cancer intervention and prevention problems. We investigate the patient-specific screening and
vaccination strategies for breast cancer and the cancers related to human papillomavirus (HPV),
representatively. Three popular healthcare analytics techniques, Markov models, regression-based
predictive models, and discrete-event simulation, are developed in the context of personalized
cancer medicine. We discuss multiple possibilities of incorporating patient-specific risk into
personalized cancer prevention strategies and showcase three practical examples. The first study
builds a Markov decision process model to optimize biopsy referral decisions for women who
receives abnormal breast cancer screening results. The second study directly optimizes the annual
breast cancer screening using a regression-based adaptive decision model. The study also
proposes a novel model selection method for logistic regression with a large number of candidate
variables. The third study addresses the personalized HPV vaccination strategies and develops a
hybrid model combining discrete-event simulation with regression-based risk estimation. Our
findings suggest that personalized screening and vaccination benefit patients by maximizing life
expectancies and minimizing the possibilities of dying from cancer. Preventive screening and
vaccination programs for other cancers or diseases, which have clearly identified risk factors and
measurable risk, may all benefit from patient-specific policies.
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1 Introduction
Over the last few years, personalized cancer medicine has emerged as a popular topic in the
healthcare community. The term personalized cancer medicine generally refers to the medical
practices for cancers that categorize patients into different groups and tailor medical decisions,
services, and products to individual characteristics of patients according to their risk of cancers
or predicted clinical responses. Although “personalized medicine” is usually described as
providing “the right patient with the right drug at the right dose at the right time”, it is involved
in all stages of care, including prevention, diagnosis, treatment and follow-up (US Food and
Drug Administration 2013). Personalized medicine provides different patients with customized
and appropriate prevention, screening, and treatment strategies, which are more effective and
cause fewer side effects compared with the standard options.
When it comes to the cancer medicine, personalizing prevention and early intervention is
extraordinarily more critical for cancer patients than for non-life-threating diseases patients. On
one hand, cancer prevention directly reduces or eliminates the chances of developing cancers and
cancer-related mortalities. On the other hand, cancer survival heavily depends upon early
diagnosis. According to the American Cancer Society (ACS), during 2017, there will be
1,688,780 newly diagnosed cancer cases and 600,920 cancer deaths in the U.S. (ACS 2017).
However, a substantial proportion of cancer cases could be effectively prevented. For example,
certain cancers caused by infectious agents, could be prevented through vaccinations, such as
human papillomavirus (HPV) vaccines for cervical cancer prevention and hepatitis B virus
(HBV) vaccines for liver cancer prevention. In addition, routine screening is known to help
reduce mortalities for breast, colon, rectum, cervix, prostate and lung cancers by early detections
(ACS 2017). Therefore, personalizing cancer prevention and invention strategies and providing
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the most appropriate or optimal medical services for different patients can greatly improve the
current cancer control practices.
This dissertation concentrates on the decision making processes of the two types of
intervention and prevention approaches, screenings and vaccinations, and aims to optimally
determine the personalized strategies for patients. For cancer screening, we focus on the
screening mammography of breast cancer, which is the most commonly diagnosed cancer in
women worldwide, and model both pre- and post-screening decisions at the individual level. For
vaccination, HPV-related cancers are analyzed with a special focus on cervical cancer, which is
the third most common female cancer worldwide (Wardle et al. 2015). We model the
personalized HPV vaccination from the perspective of HPV-related cancer prevention. Three
mainstream methodologies in healthcare analytics are adopted in this dissertation, including
Markov models, regression-based predictive model, and discrete-event simulation. We show
how to apply these popular approaches in the context of personalized cancer prevention and
propose some novel hybrid model frameworks.
In Chapter 2, we explore the personalization of post-screening biopsy referral decision. A
Markov decision process (MDP) model is developed to provide the optimal follow-up referral
decision when a patient receives abnormal screening result. The optimal policy is generated by
maximizing life expectancy generated based on every woman’s specific breast risk
characteristics. The post-screening referral decisions can be converted to pre-screening decisions
under some assumptions. The model not only considers post-screening biopsy decisions but also
offer optimal surveillance decisions for treated breast cancer patients.
Chapter 3 presents a screening decision model that provides an adaptive screening strategy
while considering the tradeoff between advantage and disadvantages of screening. We present a
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two-stage decision framework: (1) age-specific breast cancer risk estimation, and (2) annual
mammography screening decision-making based on the estimated risk. Whether a woman should
receive a mammogram is determined based on her breast cancer risk at her current age. Our “online” pre-screening decision is adaptive to a woman’s latest health status, which causes less bias
in reflecting the individual risk of every woman. Our optimal decisions outperform the existing
mammography screening guidelines in terms of the average loss of life expectancy.
Chapter 4 shifts the focus to the personalization of HPV vaccination policy. This study
models the impact of HPV vaccination at different ages on every individual woman and track
women’s courses of life to estimate the vaccination’s clinical outcomes in terms of prevented
HPV-related cancers. With the purpose of providing patient-specific HPV vaccination strategies,
especially personalized catch-up vaccination policies, we develop a discrete-event simulation
model to evaluate multiple clinical consequences after a woman gets vaccinated based on a
number of personal attributes. As our simulation model works at the individual level, we build an
HPV risk estimation model reflecting every woman’s HPV risk, which dynamically changes
over time, to support the lifetime simulation model. We use such a hybrid model to estimate the
clinical consequences and proves that the optimal HPV vaccination catch-up policy should be
personalized for different women.

References
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2 Personalized Biopsy Referral Decision Modeling for Breast Cancer Screening and
Surveillance Mammography in the Presence of Cancer Regression

Abstract
Mammography is currently the recommended method for population-based breast cancer
screening. It is also used as a surveillance approach to monitor for recurrent breast cancers for
patients already treated for early-stage breast cancer. However, all abnormal mammograms
should be followed up with additional tests, e.g., biopsy exams, to confirm the presence of cancer
due to the low specificity associated with mammography. Although biopsy is a relatively
accurate approach with negligibly low false-positive rate, it is painful and often results in
negative side-effects. This study aims to make personalized decision about whether abnormal
screening and surveillance mammogram findings should be referred for follow-up biopsy
immediately according to women's personal risk characteristics. We develop a discrete-time
finite-horizon Markov decision process model to optimize biopsy referral policies, which
maximizes women's total life expectancy. Our study provides personalized optimal follow-up
biopsy referral policies for both screening mammography and surveillance mammography based
on a woman's risk factors. We present the optimal biopsy referral policies for a typical high-risk
and a typical low-risk woman under different scenarios of clinical history. These optimal
screening policies vary with the personal risk factors significantly. Our results also demonstrate
that the optimal biopsy policies for surveillance mammography fluctuate dramatically over years.
In addition, different types of treatments for in situ breast cancer result in distinct optimal posttreatment biopsy referral policies. This study suggests that existing screening and surveillance
mammography guidelines can be improved. The optimal schedule of mammography follow-ups
should be determined on a patient-specific basis.
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2.1 Introduction
As the most common non-cutaneous form of cancer and the second leading cause of cancer
mortality among U.S. women (DeSantis et al. 2011), breast cancer has raised serious concerns
from the public health community. According to the American Cancer Society (ACS), in 2017
approximately 316,120 women will be diagnosed with breast cancer and about 40,610 women
will die from this cause. Although the advances in treatments have reduced breast cancer
mortality rates, whether the cancer is curable still relies heavily on the early detection (Berry et
al.). The ACS reported that the 5-year relative survival rate is 99% for early stage (i.e. localized
breast cancer) and 23% for late stage (i.e. distant breast cancer) (Smith et al, 2011).
Mammography is the de facto standard for breast cancer screening practice. The ACS, the
American College of Radiology (ACR) and the American Medical Association (AMA)
recommend that U.S. women should receive annual mammograms beginning at age 40 or 45.
There are a large number of clinical trials and population-based evaluations suggesting that
mammography can significantly reduce breast cancer mortality. Specifically, Tabar et al. (2003)
reported that screening mammography decreased the breast cancer mortality in women aged 40–
69 by 44%.
Mammography is not merely an effective screening procedure to early detect new cases of
breast cancers, but also intensely used as a surveillance approach to monitor for recurrent breast
cancer for patients already treated for early-stage breast cancer. Numerous studies showed that
breast cancer survivors, especially those who received breast-conserving surgeries (i.e.
lumpectomy or lumpectomy followed by radiotherapy), remain at high risk of second breast
cancers for a long time, including recurrences of the treated tumors and new primary breast
cancers (Clarke et al. 2005, Solin et al. 2005). Shaitelman et al. (2005) conducted a long-term
follow-up study on women with a history of ductal carcinoma in situ (DCIS) breast cancer and
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found that these patients still have a risk of tumor recurrence for up to 20 years after treatments.
The American Society of Clinical Oncology (ASCO) recommends women treated with breastconserving surgery (BCS) start annual surveillance mammograms one year after the initial
diagnosis and no earlier than 6-months after the radiation therapy is completed (Khatcheressian
et al. 2006). In recent studies, annual surveillance mammograms after treatments of breast
cancers were proving to significantly reduce breast cancer mortality (Lash et al. 2007).
However, mammography is not perfect. Whether a mammogram result is positive (i.e.
abnormal) is subjectively decided by a radiologist based on his/her professional skills and
experiences. Thus possible false interpretations are usually inevitable. Previous studies showed
that the risk of false positive (i.e. radiologists labeled the mammograms as positive but the
cancer is actually absent) is significant. The positive predictive value (PPV) of mammography
lies between 1.4% and 9.1%, which means the likelihood that the breast cancer really exists is
lower than 10% when a woman gets a positive mammogram result (Breast Cancer Surveillance
Consortium 2009).
To confirm the existence of cancer cells, all abnormal findings will be followed up with
additional testing, such as a biopsy exam, to confirm whether the cancer is present. Biopsy is a
medical test that conducts a pathological examination on the breast tissue sample obtained from
the suspicious breast area through a needle or a surgical procedure. It is the current “gold
standard” of evaluating suspicious screening results (Bruening et al. 2009). Although biopsy is
an accurate test with negligibly low false-positive rate (Parker et al. 1994), it is often painful and
may result in side-effects since it is an invasive procedure placing patients at the risk of
morbidities and even mortalities (Bruening et al. 2009). Due to the low PPV of mammography, it
is estimated that 70% to 90% of breast biopsies are performed unnecessarily for benign diseases
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(Zhi et al. 2007). These unnecessary follow-up exams not only resulted in large medical
expenses, but also caused the patients to suffer from pain, anxiety and multiple side-effects.
In addition to the inherent limitations of mammography technique, the occurrences of
spontaneous regression of breast cancers may also stultify some of the follow-up biopsy exams.
Zhang and Ivy (2012) summarized medical exploration of breast cancer spontaneous regression
in the literature. These medical cases showed that some cancers may disappear in the absence of
treatment. One observational study found that 22% of breast cancer tumors are likely to resolve
themselves without any treatment (Zahl et al. 2008). There are limited analytical studies
addressing this phenomenon though. Fryback et al. (2006) incorporated regression in their
simulation model. They assigned approximately 40% of the breast tumors to be limited
malignant potential tumors, which progressed to a maximum of 1cm in diameter and then
regressed after 2 years if undetected. Zhang and Ivy (2012) studied the impact of regression on
lifetime breast cancer mortality. They suggested the regression rate around 20% may make a
difference in mortality under different breast cancer treatment decisions. These studies implied
that even if the screening mammography were perfect in detecting breast cancer, a further biopsy
test may still not be necessary in the case of breast tumor regression.
Moreover, a number of prior studies showed that different women may face different risks
of breast cancer. Gail et al. (1989,1999) estimated women’s risk of breast cancer based on a
series of personal risk attributes, including age, race, age at menarche, age at birth of first child,
number of first-degree family history of breast cancer, and number of previous breast biopsy
exams. Barlow et al. (2006) established a breast cancer risk prediction model for women
receiving screening mammography using factors including age, race, body mass index (BMI),
prior breast procedure, menopause status, breast density, family history of breast cancer, and a
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prior false-positive mammogram. For early-stage breast cancer (i.e. in situ cancer) patients who
undergo BCS, numerous studies reported that different types of treatments (i.e. lumpectomy
followed with radiotherapy and lumpectomy alone) result in significantly different posttreatment recurrence risks (Boyages et al. 1999, Viani et al. 2007). Particularly, prior studies
found that different treatments result in opposite risks of recurrence on the ipsilateral and the
contralateral breasts: the addition of radiotherapy to lumpectomy reduced the risk of ipsilateral
breast cancer recurrence (IBTR) while increasing the risk of contralateral breast cancer
recurrence (CBTR) (Viani et al. 2007). Nevertheless, several studies argued that the risk of
recurrence after treatment varies over time. (Shaitelman et a. 2012, Habel et al. 1997). Therefore,
although multiple healthcare organizations provided standard guidelines for both breast cancer
screening and surveillance practices, it is important to make personalized decision about whether
an abnormal mammogram finding should be referred for biopsy according to the woman’s
specific risk characteristic, which motivates the goal of this paper: determining whether a patient
should undergo a biopsy when she receives a positive mammogram result.
There are several studies seeking to optimize the trade-off between the negative effects of
breast cancer screening and patients’ long-term benefits of early diagnosis. Maillart et al. (2008)
employed a partially observable Markov decision process (POMDP) model to evaluate different
screening mammography policies by measuring life-time breast cancer mortality risk and
expected mammogram counts. Ayer et al. (2012) formulated a POMDP model to propose an
optimal personalized screening mammography schedule based on their personal risk
characteristics associated with breast cancer, including age, race, age at menarche, age at first
live birth, and prior screening history. Chhatwal et al. (2010) investigated how to make biopsy
referral decision to maximize patients total expected quality-adjusted life years (QALY). They
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used a finite-horizon discrete-time Markov decision process (MDP) model to offer optimal
biopsy referral policies for patients with different breast cancer risk scores (i.e. a woman’s
current probability of cancer). In addition, Ayvaci et al. (2012) applied an MDP model to
optimizing biopsy referral decisions for different breast cancer risk scores under budgetary
restrictions.
Our study is different from previous studies and contributes to the literature in the following
ways: 1) our model considers the complex pathology of breast cancer by incorporating the
potential spontaneous regression of breast cancer; 2) our multidimensional model directly
provides personalized biopsy referral policy for every individual patient with different
combination of risk factors, instead of estimated risk scores; and 3) our model addresses dynamic
personalized biopsy referral policy of surveillance mammograms after treatments for early-stage
breast cancers (i.e. in situ cancer). We use an MDP model with history-dependent states to
provide optimal policies for early-stage breast cancer patients at different years after different
treatments. To the best of our knowledge, this is the first analytical study that optimizes
surveillance mammography policies after breast cancer treatments in terms of total expected
quality-adjusted life years. We also combine screening mammograms for new cancer cases with
surveillance mammograms for breast cancer follow-ups into an integrated model, which is
expected to provide a comprehensive solution of the breast cancer prevention and control
problem.
The remainder of this paper is organized as follows. Section 2.2 describes the formulation
of the MDP model. We also present several structural properties associated with the model. In
Section 2.3, we apply our model in two example cases to demonstrate how our method provides
personalized optimal biopsy referral policies. Finally, we discuss our results and the limitations
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of this paper in Section 2.4. The main medical terms used throughout the whole paper are
summarized in Table 1.
Table 1 The definitions of the main medical terms
Medical Terms
Acronym
Definition
Breast-conserving surgery
BCS
An operation to remove the breast cancer but not
the breast itself.
Contralateral breast tumor
CBTR
The cancer recurrence occurs in the opposite
recurrence
breast.
In situ cancer
Non-invasive breast cancer. The abnormal cells
have not spread outside the duct to other tissues
in the breast.
Invasive cancer
Cancer that has spread from where it started in
the breast into surrounding, healthy tissue.
Ipsilateral breast tumor
IBTR
The cancer recurrence occurs in the treated
recurrence
breast.
Lumpectomy
A surgery to remove a tumor in a breast and a
small amount of normal tissue around it
Mastectomy
A surgery to remove part of or entire breast.
Positive predictive value
PPV
The probability that a person with a positive test
result has, or will get, the disease.
Radiotherapy
The use of high-energy radiation from x-rays,
gamma rays, neutrons, protons, and other
sources to kill cancer cells and shrink tumors.
Salvage therapy
Salvage therapy is any therapy that is done in an
attempt to cure cancer following the failure of an
initial treatment.
Source: Dictionary of cancer terms (National cancer institute 2015)
2.2 Material and Methods
2.2.1 Decision Process
In this study, we assume that women strictly undergo yearly screening mammography from age
40 as recommended by the ACR and AMA guidelines. A typical screening mammography
process in one year consists of two main stages (Figure 1). The first stage is to conduct an annual
mammogram exam. If the exam result is negative, the woman is considered to be healthy and
recommended to do nothing and just wait till the next scheduled mammogram. If the woman
receives a positive mammogram, in the next stage, a decision has to be made about whether this
10

patient should be referred to a biopsy exam. Due to biopsy’s extremely low false-positive rate
(Parker et al. 1994), we assume biopsy is perfect. Thus, patients with positive biopsy findings
will be scheduled for treatment immediately. Negative findings indicate absence of breast cancer,
so that the patients should continue receiving annual mammograms.
Age t

Negative

Age t+1

Mammography
Biopsy ?

Positive

NO

Next scheduled
mammography

YES
Positive

Invasive cancer
treatment

NO

Negative

in situ cancer?
YES

Mastectomy

Lumpectomy
+ Radiotherapy

Lumpectomy

Age t+1
Surveillance
mammography

Figure 1 Annual screening process of breast cancer
Figure 1 also demonstrates how we model the process of surveillance mammography for in
situ cancer patients after being treated. As Figure 1 shows, we differentiate two types of local
treatments: mastectomy and breast-conserving surgery (i.e. lumpectomy alone and lumpectomy
with radiotherapy). For in situ patients who have received mastectomy treatments, surveillances
after mastectomy vary from person to person. For example, patients treated with prophylactic
bilateral mastectomy are no longer recommended to undergo routine follow-ups. Therefore, our
decision process only considers surveillance mammography after lumpectomy with or without
radiotherapy. For the patients who have received breast-conserving surgery, according to the
ASCO guideline on breast cancer follow-up and management (Khatcheressian et al. 2006), the
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first post-treatment mammogram should be conducted one year after the initial mammogram.
The ASCO also recommends these patients undergo yearly mammography thereafter. Hence we
assume that all the patients treated with breast-conserving surgery will carry on with annual
mammography after completion of treatments.
Our study focuses on the biopsy referral decision when a woman receives a positive
mammogram. In our decision model, whether a woman should be referred to biopsy is
determined based on six breast cancer risk factors, including the woman’s age, race, age at birth
of first child, first-degree family history of breast cancer, menopause status and clinical history
of in situ breast cancer (Table 2). The first five factors are common risk factors and their risk
associated with breast cancer is estimated by Barlow et al. (2006). We exclude the dynamic
breast cancer risk attributes (e.g. BMI) that may change over time, since the levels of these
dynamic factors in the future are unknown. The six risk factors produce 23,040 different
combinations in total.
Table 2 Risk factors of breast cancer considered in the model
Risk factors
Level
Age
40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74,7579, 80-100;
Race
White, Black, Asian, Hispanic, Other;
Age at birth of first child
<30, >=30 or Nulliparous;
First-degree family history of breast
Yes, No;
cancer
Menopause status
Premenopausal, Postmenopausal;
Clinical history of in situ breast cancer
Had the woman been diagnosed
with in situ breast cancer before?
If yes, what was the treatment
type?
How many years have passed
since the treatment?

Yes, No;
Mastectomy, Lumpectomy, Lumpectomy plus
radiotherapy;
1, 2, 3…20, 20+;
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2.2.2 MDP Model
We develop a discrete time finite-horizon Markov decision process (MDP) model to optimize
biopsy referral policies, which maximize women’s total life expectancy. For every woman with
specific background, we solve the MDP model optimally using patient-specific transition
probabilities that are estimated based on the combination of her risk factors. We formulate the
MDP model with the following components.
Decision epochs: = 40, 41, … 100, which represent a woman’s age at the current time
period. Since both screening and surveillance mammograms are performed annually according to
the ASCO, a biopsy decision will also be made on a yearly basis after a mammogram result
starting at age 40. According to the U.S. life tables (Arias 2012), we employ age 100 as the
terminating point.
States:

∈

= N, P, N , P , N , P , M, I, D ,

= 1, 2, …, 20+. We use 89 states to describe

a woman’s state after receiving a mammogram at time t. N and P represent that a woman without
clinical history of breast cancer receives a negative mammogram and a positive mammogram,
respectively. Two history-dependent states, NLn and PLn, represent that the in situ patients treated
with lumpectomy alone (L) receive negative and positive surveillance mammograms
respectively. The superscript n denotes the number of years after completion of the lumpectomy
treatment. Since women with a history of in situ cancer have risk of recurrence up to 20 years
after treatment (Shaitelman et al. 2012), n can take values from 1 to 20. If no recurrence occurs
up to 20 years after the treatment, we use a single value “20+” to represent all the succeeding
years. Thus, there are 21 states denoted by NLn or PLn. Similarly, NRn and PRn represent in situ
patients treated with lumpectomy plus radiotherapy (R) receive negative and positive
surveillance mammograms, respectively. Likewise, superscript n can take values from 1 to 20+.
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In our model, M (mastectomy), I (invasive cancer) and D (death) are treated as absorbing states,
which means once a woman enters one of these states, she will quit the decision process. Due to
the high pathological complexity of treatments for invasive cancer, we do not consider the
surveillance and follow-ups for invasive cancer patients either. Thus we use absorbing state I to
represent that a woman is diagnosed with invasive breast cancer. The absorbing state D includes
deaths from breast cancer and other causes. Considering 21 possible values of n in NLn, PLn, NRn
and PRn, our model actually includes 89 states.
Actions: " ∈ W, B . There are two options being considered: waiting (i.e. doing nothing and
waiting until the next annual mammogram) or doing a biopsy exam immediately. It is noted that
waiting is always the optimal action when the state shows a negative screening result.
Transition probability: %
transition from the state

&

| , " . Transition probability represents the possibility of

to the state st+1 at decision epoch , given that action at is taken.

Intermediate rewards: (

, " . The intermediate reward is life years assigned to the woman

at time t given that she is in state st and action at is taken. Thus the intermediate reward equals
the one year minus the disutility of the action " at current age. We assume disutility of action W

is zero and only address the disutility caused by a biopsy exam. Let ) denote the disutility of
biopsy at age t, and then the immediate reward is defined as

1
rt st ,at = 
1− dt

(

Lump-sum rewards: *

)

if at = W,
if at = B,

for st ≠ M, I, D.

. If a woman enters one of the three absorbing states, she will be

assigned with one-time lump-sum reward, which equals the total life expectancy calculated
based on her current age and state. In addition, we implement the “half-cycle correction” by
assuming that, on average, a transition from any transient state to an absorbing state occurs
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halfway through each decision epoch, instead of at the beginning or the end of an age
(Sonnenberg et al. 1993). Let ,
state

denote the life expectancy for a woman at age with

. The lump-sum reward can be calculated by

et ( st ), if st = M, I,
Rt ( st ) = 
if st = D.
0.5,
Value function: -

. Value function calculates the maximum total life expectancy given

that the woman is at age t and her current state is

. For the states associated with negative

mammograms, value functions are deterministic since action W is always selected. For the
absorbing states M, I and D, the value functions are equal to their corresponding lump-sum
rewards at current age t. Thus, the general value function is given by

(1)

For

= P, P , P , the optimal action "∗

for age t at state

is determined by
(2)

Since t = 100 is the end of the decision horizon, we assume there will be no future reward
accumulating for woman at age 100, i.e.

V100 (S100 )= 0.
2.2.3 State Transition
State transitions are action dependent, and we introduce the one-step transition diagram for the biopsy
action in Figure 2.
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Figure 2 The transition diagram for action B “do biopsy”
The state transitions from P to NLn, PLn, NRn, and PRn imply diagnoses of in situ breast cancer
and treatments. For instance, the transition from P to NL1 involves five stages: (a) the woman
with a positive mammogram chooses to do biopsy; (b) the positive mammogram is proving to be
a true-positive finding by the biopsy exam; (c) this true-positive finding is identified as in situ
cancer; (d) this patient is then treated with lumpectomy; and (e) in the first surveillance
mammography after completion of the treatment, the patient receives a negative mammogram.
Similarly, for states PLn and PRn, if biopsy exams confirm their findings are true-positive, their
transitions also involve implicit treatment stages. As an example, Figure 3 illustrates the one-step
transition processes starting from PLn with a tree structure. On one hand, if the finding at the PLn
state is confirmed by the biopsy exam to be a false positive mammogram, then the woman is
considered cancer-free at the beginning of the current decision epoch. She may stay healthy or
get a cancer recurrence during the current year. However, regardless of her true health status, the
result of the next annual mammogram can be either negative NLn+ or positive PLn+1, (no treatment
at PLn). On the other hand, if the finding at PLn turns out to be a true positive, then the woman has
a cancer recurrence. For an invasive recurrence, the patient enters the absorbing state I. For an in
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situ recurrence, we subsequently distinguish the types of treatment for the recurrence, which is
referred to as salvage therapy. The main treatment approaches of salvage therapy for in situ
cancers are the same as those for new breast cancer (i.e. lumpectomy alone, lumpectomy with
radiotherapy, and mastectomy) (Solin et al. 2001). We assume all these in situ recurrences can be
treated successfully (Fong et al. 2011). After completion of the salvage therapy, the first
surveillance mammogram can be negative or positive, which are denoted as NL1 or PL1 for
lumpectomy, and NR1or PR1 for lumpectomy with radiotherapy, respectively.
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Figure 3 One-step state transitions starting from PLn
With the tree structure, all the relevant transition probabilities are easy to calculate. For
instance, to calculate the transition probability from PLn to I under action B (i.e. % I|P , B ), we
only need to multiply all the relevant probabilities from node PLn to node I, namely, multiplying
true positive rate by the proportion of invasive cancers in all breast cancers. Details of the

17

calculation of all the transition probabilities are presented in the Appendix A.

Figure 4 The transition diagram for action W “wait”
Figure 4 is the transition diagram for the women who choose the action “wait”. We assume
that women will persistently wait until the next mammograms. As no biopsy will be performed
on the women, the presence of cancer will be unknown. Given that spontaneous regressions may
occur on some of breast cancer tumors if undetected (Fryback et al. 2006), our model considers
the cancer regression in the transitions after the action “wait” has been taken or after a falsenegative mammogram. While spontaneous regressions of invasive cancers were rarely found in
the medical literature, reported cases of spontaneous regression of in situ cancers are not
infrequent (Joensuu and Lundin 2004). Hence we assume spontaneous regressions can only
occur at in situ stage. Figure 5 shows an example of how cancer regressions get involved in the
transitions starting from P under the action “wait”. As the figure suggests, the regression may
occur when P is in fact a true positive result and corresponds to an in situ breast tumor. In
addition to P, the possibility of spontaneous regression is implicated in all transient states (i.e. N,
P, NLn, PLn, NRn and PRn) in Figure 4.
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Figure 5 The transitions starting from P in one decision epoch
There are two different types of deaths, death from breast cancer and death from other
causes in the state transitions. We assume that only patients with invasive cancer may die from
breast cancer in one-step transition. In situ cancer, as an early stage of breast cancer, is assumed
not to result in death within one year. In an earlier study using the Carolina Mammography
Registry data (Zhang 2011), the mortality rate is found to be close to zero. As a result, we
separate deaths from in situ cancer and invasive cancer in Figure 5.
2.2.4 Structural Properties
In this section, we present several structural properties of the MDP model to investigate how the
optimal solution is affected by model inputs. Based on the medical facts, we first introduce
several assumptions used to prove structural properties.
ASSUMPTION 1. Given two patients A and B at the same age t, if any one of the inequalities in
the following holds, then all the other inequalities hold.
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(b) ptA (PL1|PLn R ,B) ≥ ptB (PL1|PLn R ,B), ptA (NL1 |PLn R ,B) ≥ ptB (NL1 |PLn R ,B), ptA (PR1|PLn R ,B) ≥ ptB (PR1|PLn R ,B),
ptA (NR1 |PLn R ,B) ≥ ptB (N1R|PLn R ,B), ptA (M|PLn R ,B) ≥ ptB (M|PLn R ,B), ptA (I|PLn R ,B) ≥ ptB (I|PLn R ,B),
ptA (D|PLn R ,B) ≥ ptB (D|PLn R ,B), ptA (PLn+R1|PLn R ,W) ≤ ptB (PLn+R1|PLn R ,W), ptA ( NLn+R1|PLn R ,W) ≤ ptB (NLn+R1|PLn R ,W),
and ptA (D|PLn R ,W) ≥ ptB (D|PLn R ,W); where PLn R = PLn or PRn .
For every inequality, the left-hand side corresponds to patient A’s transition probability from a
pre-clinical stage to breast cancer diagnosis, and the right-hand side corresponds to that of
patient B. Condition (a) presents that all the transition probabilities from a screening positive
mammogram to other possible post-treatment states including death are higher for patient A than
B. Condition (b) includes all the transition probabilities from a surveillance positive
mammogram to other possible post-treatment states. If patient A and patient B both receive
breast-conserving surgeries (i.e. lumpectomy or lumpectomy with radiotherapy), then posttreatment recurrence risk of patient A is not lower than that of patient B.
Assumption 1 reflects that patient A always has a faster deterioration rate than patient B in
terms of both incidence of new primary breast cancer and cancer recurrence. It can be viewed as:
if patient A’s transition probability from any one of the pre-clinical stages (i.e. screening
mammogram or surveillance mammogram) to breast cancer diagnosis or death is higher than or
equal to that of patient B, then all her other transition probabilities from pre-clinical stages to
breast cancer diagnosis is not lower than those of patient B. This assumption also implies that if
patient A’s risk of developing new breast cancer is higher than or equal to that of patient B, then
once they are diagnosed with in situ cancer, the risk of cancer recurrence of patient A is not lower
than that of patient B. It is consistent with prior medical literature (Buist et al. 2010).
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ASSUMPTION 2.
Vt ( T,B ) = V ( PL1 )
+V ( N L1 )
+V ( PR1 )

+V ( I )

Pt ( PL1 | P,B)
Pt ( P |P,B ) + Pt ( N |P,B ) + Pt ( P |P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)
1
L

1
L

1
R

Pt ( N L1 | P,B)
Pt ( PL1|P,B ) + Pt ( N L1 |P,B ) + Pt ( PR1|P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)

Pt ( PR1 | P,B)
Pt ( PL1|P,B ) + Pt ( N L1 |P,B ) + Pt ( PR1|P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)

+V ( N R1 )
+V ( M )

,

Pt ( N R1 | P,B)
Pt ( P |P,B ) + Pt ( N |P,B ) + Pt ( P |P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)
1
L

1
L

1
R

Pt ( M | P,B)
Pt ( P |P,B ) + Pt ( N |P,B ) + Pt ( P |P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)
1
L

1
L

1
R

Pt (I | P,B)
,
Pt ( P |P,B ) + Pt ( N |P,B ) + Pt ( P |P,B ) + Pt ( N R1 |P,B ) + Pt ( M|P,B ) + Pt (I | P,B)
1
L

1
L

1
R

and
Vt ( NP,B ) = V ( N )

Pt (N|P,B)
Pt (P|P,B)
,
+V ( P )
Pt ( N|P,B ) + Pt (P|P,B)
Pt ( N|P,B ) + Pt (P|P,B)

then Vt ( NP,B ) ≥ Vt ( T,B ) ≥ Vt ( D ) .

In this assumption, we denote the post- treatment total life expectancy of a woman with biopsyverified true positive mammogram by Vt ( T,B ) , where T and B represents treatment and biopy,
respectively. Vt ( NP,B ) corresponds to the total life expectancy of a women with biopsy-verified
false positive mammogram. NP means the women will continue undergoing mammography,
which will turn out to be either negative or positive. The assumption indicates that the postbiopsy life expectancy after a negative (i.e. benign) biopsy result is always higher than or equal
to that after a positive (i.e. malignant) biopsy result. The same assumption has been made in
some other breast cancer screening studies (Chhatwal et al 2010).
Theorem 1. For any given patient, there exists a threshold of biopsy disutility ) ∗ , ∀ , such that

W
a ( st ) = 
B
*
t
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if dt > d t* ,
if dt ≤ d t* .

(3)

According to Equation (1) in Section 2.2,
d t* =

∑

st +1∈S

vt +1 ( st +1 ) pt ( st +1 |st , B) −

∑

st +1∈S

vt +1 ( st +1 ) pt ( st +1 |st , W).

Thus ) ∗ is the gain of life expectancy brought by doing biopsy. Theorem 1 implies that only
when the disutility of biopsy does not exceed the gain of life expectancy brought by a biopsy
exam, will doing biopsy be an optimal choice. Therefore, ) ∗ provides a measurement to assess

how likely a patient makes a biopsy decision. Obviously, a higher ) ∗ indicates that the patient is

more apt for biopsy relative to another patient with a lower ) ∗ .
Proposition 1. Let - 0

and - 1

respectively. Under assumption 1, - 0

be the value functions of patient A and patient B,
≤ -1

, ∀ and ∀ .

Proposition 1 confirm the intuition that the higher risk of breast cancer is, the lower life
expectancy of a patient will be.
Proposition 2. Let * 3 and * 4 3 be the two possible lump-sum rewards at state I for a

patient, respectively. If * 3 ≥ * 4 3 , then -

≥ -4

, ∀ and ∀ .

Corollary 1. Let * 0 6 and * 1 6 be the lump-sum rewards of state M for patient A patient

B, respectively. If * 0 6 ≥ * 1 6 , then - 0

≥ -1

Proposition 2 and corollary 1 mean that -

, ∀ and ∀ .

is nondecreasing in * 3 as well as * 6 .

The clinical significance of these two conclusions is that the better prognosis for invasive cancer
patients or in situ cancer patients who received mastectomy, the higher life expectancy will be
for all women undergoing annual mammography.
The proofs of all the conclusions above are presented in Appendix B.

2.3 Results
In this section, we first describe how we use the data from various sources to estimate the model
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parameters in Section 2.3.1. Then Section 2.3.2 presents the computational results by
implementing the MDP model. Finally, we perform sensitivity analyses on several model
parameters in Section 2.3.3.
2.3.1 Parameter Estimation
Since there is no single dataset that reports all the clinical data regarding epidemiology, diagnosis
and treatment of breast cancer, we resort to multiple sources to estimate the model parameters
(Table 3). In addition, the value of regression rate is assumed to be 20% in our base case analysis
(Zhang and Ivy 2012). In the remainder of this section, we explain how we obtain the parameter
estimation for calculating transition probabilities, intermediate reward and lump-sum reward.
Table 3 The data source for parameter estimation
Parameter
type

Parameter

Data source

Incidence

Breast Cancer Surveillance Consortium
(BCSC) dataset
BCSC dataset
BCSC 2009

Age-specific
Age-specific

Arias 2012
Zhang 2011
Buist et al. 2010

Age-specific
Age-specific
Age-specific

Wapnir et al. 2011, Shaitelman et al. 2012

Year-specific

Laboratory for Quantitative Medicine

Age-specific

Prevalence
Sensitivity, specificity and PPV of
mammography
Mortality for the general population
One-year mortality of invasive cancers
Percentages of treatment types for in situ
cancer
Breast cancer recurrent rate
Life expectancy for invasive cancer patients

Case-specific

The incidences of in situ breast cancers and invasive cancers are estimated using a raw dataset
from the BCSC, which consists of 1,007,660 women’s screening mammograms from 1996
through 2002. This dataset reports one observation randomly selected from every woman’s
screening history. Each observation reports a woman’s age (by 5-year age group), menopausal
status, race, age at first birth, family history of breast cancer and diagnosis information within 1
year of the screening mammogram. For women with a specific combination of risk levels, we
treat them as one risk group, and use the diagnosis information to derive the incidence rate of
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breast cancer, as well as the proportions of in situ cancers and invasive cancers for this group.
Since only the women aged 35–84 are included in this dataset, we use the incidence of woman
aged 80–84 as the incidence for all the women older than 80. We also use this assumption to
process all other data that do not cover all age groups of 40–100 to fit our decision horizon.
Recurrence rate of breast cancer after treatment is different from the incidence of new breast
cancer. In addition, the magnitude of recurrence risk fluctuates over the years after completion of
treatment. Due to scarcity of data, we assume the recurrence rates to be the same for all women.
We adopt the yearly incidence rate of recurrence for each of the 20 years after completion of
lumpectomy with radiotherapy reported by Shaitelman et al. (2012). The yearly recurrence rates
associated with lumpectomy alone are estimated based on Viani et al.’s meta-analysis (2007),
which investigated the effect of the addition of radiation therapy to lumpectomy for in situ cancer
on IBTR (ipsilateral breast tumor recurrence) and CBTR (contralateral breast tumor recurrence).
Let P IBTR , P CBTR , P IBTR and P CBTR denote the probabilities of IBTR and
CBTR after lumpectomy and the probabilities of IBTR and CBTR after lumpectomy with
radiation in the nth year after treatment, respectively. We have
PRn ( IBTR ) /PLn ( IBTR ) = 0.6,
PRn ( CBTR ) / PLn ( CBTR ) = 1.53.
Since no study discusses age-specific annual death rates of untreated invasive breast cancer,
we estimate these rates for invasive cancer patients based on the one-year treated mortality using
the Carolina Mammography Registry data (Zhang 2011). To adjust for the untreated breast
cancer, we use Verkooijen et. al’s study (Verkooijen et al. 2005) on the effect of refusal of
treatment on mortality, i.e., : DUC = 3: DC , where : DUC and := DC are the annual
mortality rates for untreated invasive cancer patients and treated invasive cancer patients at age t,
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respectively.

Table 4 The distribution of treatment types by age
First-time cancer and CBTR
IBTR
Treatment
40-49
50-59 60-69 70-79
≥80
Lumpectomy alone
25.8% 27%
31%
37.6% 53.2% 0
Lumpectomy with
37.2% 37%
35%
28.4% 16.8% 0
radiotherapy
Mastectomy
37%
36%
34%
34%
30%
100%
Source: Baxter et al. 2004
IBTR = ipsilateral breast tumor recurrence, CBTR = contralateral breast tumor recurrence
As explained in Section 2.2.3, the state transitions involve implicit treatment stage. Here we
differentiate the probabilities of choosing different types of treatments for new cancers from
those of choosing different salvage treatments for cancer recurrence. According to Zujewski et al.
(2011), the use of breast-conserving surgery (BCS), including lumpectomy with or without
radiotherapy, is correlated with age. Older patients are more likely to receive BCS than younger
patients, while the use of radiotherapy following a BCS decreased with age. We adopt the
treatment distribution of new in situ breast cancers reported by Baxter et al. (2004). With respect
to cancer recurrences, mastectomy is considered to be the standard salvage therapy when IBTR
occurs for patients who had BCS (Jatoi and Kaufmann 2010). An earlier study also reported that
the vast majority of the patients who experienced in situ IBTR were treated with mastectomy
(Solin et al. 2001). Although several cases of further BCS in patients previously receiving
lumpectomy without radiotherapy have been reported, Harris and Solin found that a second BCS
and mastectomy treatment result in nearly equivalent post-treatment survivals for in situ
recurrence (Harris and Solin 2000). Therefore, we assume all the patients previously treated with
lumpectomy with or without radiation will choose mastectomy as the salvage therapy when in
situ IBTR occurs. However, for CBTR, to the best of our knowledge, there is no study available
discussing the distribution of treatment types. Since CBTR is a tumor occurring in the
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contralateral breast, which is independent of the primary breast tumor, we assume it has the same
treatment distribution as the new cancer. Table 4 summarizes all the probability distributions of
treatment types in different cases.

2.3.1.1 Parameters for State Transitions
In this section, we introduce parameter estimation for intermediate and lump-sum rewards.
Biopsy is an invasive procedure that may place the patients at risk of morbidities and even
mortalities. Thus, we assume the disutility of doing biopsy to be 2 weeks (Velanovich et al.
1995). As a woman gets older, the risk and side-effects caused by biopsy also become more
harmful. Hence, we assume the disutility associated with biopsy is inversely proportional to the
age-specific EQ-5D scores, which reflects varying negative impacts of biopsy on women’s
health at different ages. EQ-5D is a utility-based measure of health status and widely used in
clinical and economic evaluation of health care (EuroQol Group 1990). Here we employ the agespecific mean EQ-5D score reported by Saarni et al. (2006). All the disutility estimates are
presented in Table 5.

Table 5 Disutility of Biopsy
Age group

40-44

45-54

55-64

65-74

75-84

>85

EQ-5D values

0.911

0.870

0.816

0.776

0.633

0.446

Disutility of biopsy (week)

2

2.09

2.23

2.35

2.88

4.09

The lump-sum rewards for absorbing states , M and , I , are determined based on a
patient’s life expectancy. Hillner et al. (1996) showed that in situ cancers treated with
mastectomy reduces women’s life expectancy by 1.8% over a 20-year period. Based on this
finding, we assume that the discounting factor of mastectomy that shortens women’s life
expectancy is 1.8%. Therefore, , M is equal to the discounted population-based life
expectancy of American women aged t, which is available in the United States life tables (Arias
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2012). In addition, we use the breast cancer outcome calculator
(http://www.lifemath.net/cancer/breastcancer/outcome/index.php) developed by the Laboratory
for Quantitative Medicine to estimate the life expectancies (i.e. , I ) for treated invasive cancer
patients. We use ages and the mean size of screening detected invasive tumors (BCSC 2009) as
the inputs for the calculation.

2.3.2 Experiment Results
Table 6 The personal status of the risk factors for example cases
Risk factors
Patient A
Age
40
Race
white
Age at birth of first child
>30
First-degree family history of breast Yes
cancer
Menopause status
Premenopausal
Clinical history of in situ breast
cancer
Scenario 1
None
Scenario 2
Scenario 3

in situ cancer is detected
at age 45
in situ cancer is detected
at age 70

Patient B
40
Asian
<30
No
Premenopausal
None
in situ cancer is detected
at age 45
in situ cancer is detected
at age 70

In this section, we present two example cases to show the optimal biopsy referral policies for
different women. The personal breast cancer risk attributes of the two examples are listed in
Table 6. In these two case studies, we assume both patient A and patient B will turn into
postmenopausal at age 51 based on the mean age of natural menopause reported by Kato et
al.(1998). Patient A and patient B are representative of high-risk and low-risk women,
respectively. Based on the BCSC dataset, the breast cancer incidence of the low-risk women
represented by patient A is estimated to be 0.0049, while that of high-risk women represented by
patient B is 0.0108. Therefore, patient A is expected to undergo more intensive screenings and
follow-up biopsy exams for detecting breast cancer than patient B.
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We study three scenarios to show the optimal policies for women with different clinical
histories. Table 7 presents the optimal biopsy referral policies for the two women without clinical
history on a 60-year horizon (i.e. from age 40 through age 99). In order to reach the highest life
expectancy, these two women should follow the optimal policies until they reach age 100 or they
are diagnosed with breast cancer. While patient A is recommended to receive 46 biopsies among
60 positive mammograms, patient B is only recommended to undergo 42 biopsies. This outcome
is consistent with the assumption that patient A bears higher breast cancer risk than patient B
does.

Table 7 The optimal biopsy referral policies for two patients in scenario 1 from age 40 to 90
Age

40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69

Patient A W W W W W B B B B B W W B B B B B B B B B B B B B W W W W W
Patient B W W W W W W W W W W B B B B B B B B B B B B B B B W W W W W
Age

70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 91 92 93 94 95 96 97 98 99

Patient A B B B B B B B B B B B B B B B B B B B B B B B B B B B W W
Patient B B B B W B B B B B B B B B B B B B B B B B B B B B B B W W

B= do biopsy, W=wait.
In this model, the optimal decisions at different ages depend on multiple variables, including
the incidence rate, ratio of invasive cancer to all breast cancers, disutility of biopsy, death rate
from invasive cancer, and distribution of treatment types. On the one hand, the monotonicity of
these variables are not consistent. On the other hand, even some of these variables are not
monotonic and fluctuate over age. As a result, our optimal policies demonstrate non-monotone
patterns. For instance, patient A is recommended to do biopsy from age 45 but skip biopsy at
ages 50 and 51. According to the data, the incidence rates of breast cancer for patient A from age
40 to 44 are lower than those after age 44, which explains why patient A should start follow-up
biopsy from age 45. However, the incidence rates of breast cancer at ages 50 and 51 are not
significantly different from those between ages 45 and 60. This optimal action “wait” at ages 50
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and 51 is probably because of a relatively low proportion of invasive cancers among new cancer
cases at these two ages for patient A, since a lower possibility of developing malignant breast
cancer means less necessity for biopsy exam. In a similar manner, the optimal policy flips
between “W” and “B” with age to reach an optimal tradeoff among different non-monotone
determinants.
Our results partly explain the controversy on screening guidelines in the public health
community. While the ACS recommends women to start receiving routine mammography from
age 45, the U.S. Preventive Services Task Force (USPTF) and the American College of
Preventive Medicine (ACMP) suggest the starting age of mammography should be 50 (Oeffinger
et al. 2015, Siu 2016). However, our results show that the first years of starting biopsies are age
50 and age 45 for the patients with low risk and high risk, respectively. Since both women are
not recommended to do biopsy before these two ages, no matter if the mammogram is positive or
negative, their mammography decisions should also start from age 50 and age 45 respectively.
This result also aligns with some individual studies, which argue that women should begin
mammography screenings between age 45 and 50 (Antman and Shea 1999).
The patient B’s optimal referral policy recommends women suspend biopsies at age 50 and 51
after five consecutive biopsy recommendations between age 45 and age 49, which implicitly
reflects the USPSTF’s concern that the potential benefit of frequent breast cancer screening
before age 50 cannot offset the cumulative harms caused by potential false-positive results and
potential over-diagnosis of mammograms as well as follow-up biopsies.
It is worth noting that both patients are recommended to skip mammograms between ages 65
and 69, consistent with some clinical studies indicating that recall rates were significantly lower
for women aged 65–69 compared with women aged 50–64 (Moss et al. 2011). The experimental
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results also echo some other researchers’ efforts on the improvement of screening
mammography. For instance, we recommend patient A skip biopsies as well as mammograms in
4 out of 9 years from age 66 to age 74. In addition, patient B, who bears relatively lower risk of
breast cancer, is recommended to skip 5 out of 9 biopsies as well as mammograms during the
same interval. To some extent, it coincides with Braithwaite et al.’s study on women undergoing
annual mammograms between ages 66 and 89, which suggests that women aged 66 to 74 years
should reduce the frequency of routine screenings to biennial (Braithwaite et al. 2013).
Therefore, from the perspective of breast cancer prevention, age 66 to age 74 can be viewed as a
“low-risk interval” that does not need intensive screenings.

Table 8 The 20-year optimal post-treatment biopsy referrals for patients in scenarios 2 and 3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
state PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Age
Patient
B B B B W W W W W B B B B B W W W W W W
A
Patient
B B B B W W W W W B B B B B W W W W W W
B
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
state PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Age
Patient
B B B B W W W W W W W W W W B B B B B B
A
Patient
B B B B W W W W W W W W W W B B B B B B
B
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

state PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL PL
71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Age
Patient
B B B B B W W W W W B W W W B B B B B W
A
Patient
B B B B B W W W W W B W W W B B B B B W
B
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
state PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR
71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Age
Patient
B B B B W W W W W W W W W W B B B W W W
A
Patient
B B B B W W W W W W W W W W B B B W W W
B
B= do biopsy, W=wait.
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Next, we investigate the cases of the patients with clinical history of in situ cancer. Since we
use the same yearly recurrence rates for all patients, we expect there is little difference between
different patient’s optimal post-treatment biopsy referral policies. Therefore, only age, number of
years after treatment, and treatment option are determinants of the optimal biopsy policies for
these cases. In scenarios 2 and 3, two patients are diagnosed with in situ breast cancer at age 45
and age 70, respectively. Table 8 presents the optimal biopsy referral policies for the two
scenarios under different treatments. As expected, the two patients have identical optimal biopsy
referral policies if they are in the same post-treatment year and received the same treatment.
Moreover, neither lumpectomy alone nor lumpectomy with radiotherapy indicates a significant
predominance in the total number of optimal biopsy decisions.

2.3.3 Sensitivity Analysis
We conduct two sensitivity analyses by varying two parameters: regression rate and disutility of
biopsy. Since regression rate reflects “self-healing” property of breast tumors, the larger the
regression rate is, the less likely that the patient should receive a follow-up biopsy. Figure 6
shows the decreasing trend of total number of optimal biopsy decisions with the increase of
regression rate. The inflection points of regression rate for patient B is approximately 35%, while
varying regression rate for patient A does not impact her optimal biopsy referral policy.
These results suggest that the spontaneous regression of breast tumors does not necessarily
influence our biopsy referral policy. As compared to patient B, patient A’s risk of developing
breast cancer is too high to be counteracted by potential spontaneous regression of in situ tumor.
It is worth mentioning that the decrease in the total number of optimal biopsy decisions
predominantly occurs in young women in our finding. The proportion of in situ cancers among
all breast cancer cases is very low among very elderly (Barlow et al. 2006). Particularly, in our
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dataset, the percentage of in situ cancers is close to zero for the patients older than 80. Therefore,
the spontaneous regression of in situ tumors has little effect on the biopsy decisions for older
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Figure 6 The trend of total number of optimum biopsies from age 40 through 100 when
varying the regression rate
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Figure 7 The trend of total number of optimum biopsies from age 40 through 100 when
varying the biopsy disutility
We then vary the magnitude of biopsy disutility by multiplying the base value (i.e. 2 weeks
at age 40) using different coefficients (Fig 7). When the multiplier is set to zero, which means
biopsy has no negative impact on patient’s health so that doing biopsy would not reduce
intermediate life years at the current decision epoch, the optimal action is always undertaking
biopsy. As the disutility of biopsy increases, the patient is increasingly likely opt to “wait” when
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receiving a positive mammogram, since the reduction of mortality by choosing biopsy is no
longer sufficient to offset inherent harm and risk posed on health brought by the biopsy exam.
When the disutility of biopsy increases threefold (6 weeks at age 40), both patient A and patient
B should never do biopsy in their lifetime.

2.4 Conclusion and Limitations
2.4.1 Discussion
This study provides personalized optimal follow-up biopsy referral policies for both screening
mammography and surveillance mammography. We aim at analyzing the common overdiagnosis problem in the current annual mammography practice of breast cancer. This problem is
formulated as an MDP model with a value function of maximizing total life expectancy.
Although we focus on decisions of biopsy referring after positive mammograms, our policy is in
fact equivalent to a mammography guideline. If a patient is recommended not to do biopsy in the
current year, the corresponding mammogram is actually also unnecessary, since no matter
whether the outcome is positive or negative, the woman will wait until the next mammogram.
Previous medical literature suggests that the dose required for a mammogram is so small that the
associated risk of radiation exposure is negligible (Berry et al. 2005). Therefore, it is reasonable
to assume that mammography is a harmless exam without significant disutility. Removing the
mammograms associated with optimal decision of “wait” from our model has no effect on model
output. As a result, our study suggests that existing mammography guidelines proposed by the
healthcare organizations, which recommend periodic screening mammography for all women,
can be improved. The schedule of mammography should be determined on a patient-specific
basis.
We also discuss the influence of potential spontaneous regression of breast tumor on the
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biopsy referral decision. Despite lack of sufficient direct evidence, there have been concerns that
spontaneous regression of tumor may lead to a percentage of over-diagnosis in the breast cancer
screening practice. Our sensitivity analysis finds that regression has no effect on high risk
women, but a certain level of regression rate may reduce the need for biopsy exams in low-risk
women.
In addition, our model addresses the surveillance mammography after completion of
treatment for in situ cancers. Our case studies demonstrate that surveillance mammography
schedules can also be personalized. Although we have only three-dimensional determinants (i.e.
age, number of years after treatment, and treatment type) for biopsy referral policy of following
surveillance mammography, our results still reveal the differences between the optimal policies
of people with different combinations of determinants. Previous studies showed that the
recurrence risk after breast-conserving surgery varies nonlinearly over time and risk factors for
recurrence need to be viewed differently based on the time frame of follow-ups (Shaitelman et a.
2012, Braithwaite at al. 2013). Our experimental results demonstrate that the optimal biopsy
policies fluctuate dramatically over years, which are consistent with the non-monotone pattern of
post-treatment recurrence risk over a long-term time horizon.
Moreover, although radiotherapy after lumpectomy is proving to significantly reduce the risk
of local recurrence after treatment of in situ cancer, our study does not show that patients with
lumpectomy plus radiotherapy will perform less biopsies than those with lumpectomy alone,
which is a somewhat counter-intuitive result since the good performance of postoperative
radiotherapy in reducing local recurrence has been emphasized for years.

2.4.2 Limitations and Future work
There are several limitations in our study. First, we use a general set of yearly recurrence rates
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for all patients. In fact, previous studies found several major risk factors associated with breast
cancer are also related to recurrence rate after initial diagnosis of in situ cancer (Buist et al.2010).
Future work using patient-specific yearly recurrence rates may provide more realistic
personalized biopsy referral polices for surveillance mammography. Second, our MDP model
only considers two options, skipping or doing biopsy. As a matter of fact, there exist more
approaches to early detect breast cancer, such as breast self-examination. Therefore, our biopsy
referral policy is very conservative, since introducing self-examination would potentially reduce
mortality brought by skipping mammograms and follow-up biopsies. Including breast selfexamination as an option in the model will represent the real situations better. Third, in order to
fit our MDP model, the risk factors we used to categorize patients do not include any dynamic
breast cancer risk factors (e.g. BMI and breast density), which may change over time. For
instance, since we do not know a woman’s BMI at her next age, it is very difficult to determine
her breast cancer risk in the following year as well as all future years when we consider BMI as a
determinant of breast cancer risk. As a result, we are unable to calculate the associated transition
probabilities. There are a lot of dynamic breast cancer risk factors identified in our raw dataset,
including BMI, prior breast procedure, breast density, result of last mammogram and hormone
therapy use. We plan to incorporate the effects of these dynamic factors in our future work.
Lastly, the experimental results of the optimal biopsy referral policies are completely datadriven, which are inevitably impacted by the statistical noise and numerical errors in the input
data. As a result, the optimal policy may not be a generally optimal. The flips in the optimal
policies are therefore insufficiently justified. Our future research will employ some datasmoothing techniques to mitigate these undesirable impacts from the input data.
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Appendix

A. Estimation for Transition Probabilities
Parameters
P DO = annual death probability (excluding death of breast cancer)
P DUC = annual death probability of untreated invasive breast cancer patient
P DC = annual death probability of treated invasive cancer patient
P NC − C = annual incidence rate of new breast cancer
P NC − NC = 1− P NC − C
P ins|C = proportion of in situ cancers among all breast cancers
P inv|C = proportion of invasive cancers among all breast cancers
P NC|Negative = percentage of negative mammograms in which no cancer exists.
P C|Negative = percentage of negative mammograms in which cancers exist.
P NC|Positive = percentage of positive mammograms in which no cancer exists.
P C|Positive = percentage of positive mammograms in which cancers exist.
P Negative|NC = percentage of non-cancers that are interpreted as negative mammograms
P Positive|NC = percentage of non-cancers that are interpreted as negative mammograms
P Negative|C = percentage of cancers that are interpreted as negative mammograms
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P Positive|C = percentage of cancers that are interpreted as negative mammograms
P R = annual regression rate of in situ cancer
P L|ins = probability of choosing lumpectomy treatment for in situ patients
P R|ins = probability of choosing lumpectomy with radiotherapy treatment for in situ patients
P M|ins = probability of choosing mastectomy treatment for in situ patients
P IBTR = recurrence rate of IBTR in the nth year after completion of lumpectomy
P CBTR = recurrence rate of CBTR in the nth year after completion of lumpectomy
P IBTR = recurrence rate of IBTR in the nth year after completion of lumpectomy with
radiotherapy

P CBTR = recurrence rate of CBTR in the nth year after completion of lumpectomy with
radiotherapy

P ins, IBTR|CG = proportion of in situ IBTRs in all the recurrences in the nth year after
completion of lumpectomy

P inv, IBTR|CG = proportion of invasive IBTRs in all the recurrences in the nth year after
completion of lumpectomy

P ins, CBTR|CG = proportion of in situ IBTRs in all the recurrences in the nth year after
completion of lumpectomy

P inv, CBTR|CG = proportion of invasive CBTRs in all the recurrences in the nth year after
completion of lumpectomy
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P ins, IBTR|CG = proportion of in situ IBTRs in all the recurrences in the nth year after
completion of lumpectomy with radiotherapy

P inv, IBTR|CG = proportion of invasive IBTRs in all the recurrences in the nth year after
completion of lumpectomy with radiotherapy

P ins, CBTR|CG = proportion of in situ IBTRs in all the recurrences in the nth year after
completion of lumpectomy with radiotherapy

P inv, CBTR|CG = proportion of invasive IBTRs in all the recurrences in the nth year after
completion of lumpectomy with radiotherapy

Probabilities
Starting from N
p N|N, W = P NC|Negative I1 − P DO JIP NC − NC P Negative|NC +
P NC − C P Negative|C J + P C|Negative I P ins|C I1 −

P DO J IP R P Negative│NC + 1 − P R P Negative│NC J + P inv|C 1 −
P DO 1 − P DUC P Negative|C J

p D|N, W = P NC|Negative P DO + P C|Negative LP ins|C P DO +
P inv|C M1 − I1 − P DO JI1 − P DUC JNO
p P|N, W = 1 − p N|N, W − p D|N, W
Starting from P
Action: B
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p P|P, B = P NC|Positive 1 − P DO )(P NC − NC P Positive|NC + P NC −
C P Positive|C )

p N|P, B = P NC|Positive 1 − P DO (P NC − NC P Negative|NC + P NC −

C P Negative|C )

p P |P, B = P C|Positive P ins|C P L|ins I1 − P DO J PL1 − M1 − P IBTR NM1 −
P CBTR NO P Positive|C + M1 − P IBTR NM1 − P CBTR NP Positive|NC Q
p N |P, B = P C|Positive P ins|C P L|ins I1 − P DO J PL1 − M1 − P IBTR NM1 −
P CBTR NO P Negative|C + M1 − P IBTR NM1 − P CBTR NP Negative|NC Q
p P |P, B = P C|Positive P ins|C P R|ins I1 − P DO J PL1 − M1 − P IBTR NM1 −
P CBTR NO P Positive|C + M1 − P IBTR NM1 − P CBTR NP Positive|NC Q
p N |P, B = P C|Positive P ins|C P R|ins I1 − P DO J PL1 − M1 − P IBTR NM1 −
P CBTR NO P Positive|C + M1 − P IBTR NM1 − P CBTR NP Positive|NC Q
p M|P, B = P C|Positive P ins|C P M|ins
p I|P, B = P C|Positive P inv|C

p D|P, B = 1 − p P|P, B − p N|P, B − p P |P, B − p N |P, B − p P |P, B −
p N |P, B − p M|P, B − p I|P, B

Action: W
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p N|P, W = P NC|Positive I1 − P DO JIP NC − NC P Negative|NC +
P NC − C P Negative|C J + P C|Positive I P ins|C I1 −

P DO J IP R P Negative│NC + 1 − P R P Negative│NC J + P inv|C 1 −
P DO 1 − P DUC P Negative|C J

p D|P, W = P NC|Positive P DO + P C|Positive LP ins|C P DO + P inv|C M1 −
I1 − P DO JI1 − P DUC JNO
p P|P, W = 1 − p N|P, W − p D|P, W

Starting from RST
p N

&

|N , W = P NC|Negative I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O +
P C|Negative

LIP ins, IBTR|CG + P ins, CBTR|CG JI1 −

P DO J MP R P Negative|NC + I1 − P R JP Negative|C N + IP inv, IBTR|CG +
P inv, CBTR|CG JI1 − P DO JI1 − P DUC JP Negative|C O
p D|N , W = P NC|Negative P DO + P C|Negative LIP ins, IBTR|CG +
P ins, CBTR|CG JP DO + IP inv, CBTR|CG + P inv, CBTR|CG J M1 − I1 − P DO JI1 −
P DUC JNO
p P

&

|N , W = 1 − p N G& |N G , W − p D|N G , W
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Starting from UST
Action: B
p P

&

|P , B = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Positive|C + I1 − P IBTR JI1 − P CBTR JP Positive|NC O
p N

&

|P , B = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O
p P |P , B = P C|Positive I1 − P DO J P ins, CBTR|CG P L|ins PL1 −
M1 − P IBTR NM1 − P CBTR NO P Positive|C + M1 − P IBTR NM1 −
P CBTR NP Positive|NC Q
p N |P , B = P C|Positive I1 − P DO JIP ins, CBTR|CG P L|ins J PL1 −
M1 − P IBTR NM1 − P CBTR NO P Negative|C + M1 − P IBTR NM1 −
P CBTR NP Negative|NC Q
p P |P , B = P C|Positive I1 − P DO J P ins, CBTR|CG P R|ins PL1 −
M1 − P IBTR NM1 − P CBTR NO P Positive|C + M1 − P IBTR NM1 −
P CBTR NP Positive|NC Q
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p N |P , B = P C|Positive I1 − P DO JIP ins, CBTR|CG P R|ins J PL1 −
M1 − P IBTR NM1 − P CBTR NO P Negative|C + M1 − P IBTR NM1 −
P CBTR NP Negative|NC Q
p I|P , B = P C|Positive IP inv, IBTR|CG + P inv, CBTR|CG J

p M|P , B = P C|Positive IP ins, IBTR|CG + P ins, CBTR|CG P M|ins J
p D|P , B = 1 − p P

&

|P , B − p N

&

|P , B − p P |P , B − p N |P , B −

p P |P , B − p N |P , B − p I|P , B − p M|P , B
Action: W
p N

&

|P , W = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O +
P C|Positive LIP ins, IBTR|CG + P ins, CBTR|CG JI1 −
P DO J MP R P Negative|NC + I1 − P R JP Negative|C N + IP inv, IBTR|CG +
P inv, CBTR|CG JI1 − P DO JI1 − P DUC JP Negative|C O
p D|P , W = P NC|Positive P DO + P C|Positive LIP ins, IBTR|CG +
P ins, CBTR|CG JP DO + IP inv, CBTR|CG + P inv, CBTR|CG J M1 − I1 − P DO JI1 −
P DUC JNO
p P

&

|P , W = 1 − p N G& |P G , W − p D|P G , W
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Starting from RVT
p N

&

|N , W = P NC|Negative I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O +
P C|Negative

LIP ins, IBTR|CG + P ins, CBTR|CG JI1 −

P DO J MP R P Negative|NC + I1 − P R JP Negative|C N + IP inv, IBTR|CG +
P inv, CBTR|CG JI1 − P DO JI1 − P DUC JP Negative|C O
p D|N , W = P NC|Negative P DO + P C|Negative LIP ins, IBTR|CG +
P ins, CBTR|CG JP DO + IP inv, CBTR|CG + P inv, CBTR|CG J M1 − I1 − P DO JI1 −
P DUC JNO
p P

&

|N , W = 1 − p N G& |N G , W − p D|N G , W

Starting from UVT
Action: B
p P

&

|P , B = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Positive|C + I1 − P IBTR JI1 − P CBTR JP Positive|NC O
p N

&

|P , B = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O
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p P |P , B = P C|Positive I1 − P DO J P ins, CBTR|CG P L|ins PL1 −
M1 − P IBTR NM1 − P CBTR NO P Positive|C + M1 − P IBTR NM1 −
P CBTR NP Positive|NC Q
p N |P , B = P C|Positive I1 − P DO JIP ins, CBTR|CG P L|ins J PL1 −
M1 − P IBTR NM1 − P CBTR NO P Negative|C + M1 − P IBTR NM1 −
P CBTR NP Negative|NC Q
p P |P , B = P C|Positive I1 − P DO J P ins, CBTR|CG P R|ins PL1 −
M1 − P IBTR NM1 − P CBTR NO P Positive|C + M1 − P IBTR NM1 −
P CBTR NP Positive|NC Q
p N |P , B = P C|Positive I1 − P DO JIP ins, CBTR|CG P R|ins J PL1 −
M1 − P IBTR NM1 − P CBTR NO P Negative|C + M1 − P IBTR NM1 −
P CBTR NP Negative|NC Q
p I|P , B = P C|Positive IP inv, IBTR|CG + P inv, CBTR|CG J

p M|P , B = P C|Positive IP ins, IBTR|CG + P ins, CBTR|CG P M|ins J
p D|P , B = 1 − p P

&

|P , B − p N

&

|P , B − p P |P , B − p N |P , B −

p P |P , B − p N |P , B − p I|P , B − p M|P , B
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Action: W
p N

&

|P , W = P NC|Positive I1 − P DO J LM1 − I1 − P IBTR JI1 −

P CBTR JN P Negative|C + I1 − P IBTR JI1 − P CBTR JP Negative|NC O +
P C|Positive LIP ins, IBTR|CG + P ins, CBTR|CG JI1 −
P DO J MP R P Negative|NC + I1 − P R JP Negative|C N + IP inv, IBTR|CG +
P inv, CBTR|CG JI1 − P DO JI1 − P DUC JP Negative|C O
p D|P , W = P NC|Positive P DO + P C|Positive LIP ins, IBTR|CG +
P ins, CBTR|CG JP DO + IP inv, CBTR|CG + P inv, CBTR|CG J M1 − I1 − P DO JI1 −
P DUC JNO
p P

&

|P , W = 1 − p N G& |P G , W − p D|P G , W

B. Proofs of Structural Properties
Proof of Theorem 1.
If ) > ) ∗ ,
) > ∑[\]^ ∈_ Z
∴ ∑[\]^ ∈_ Z

&

&
&

&

%

%
&

&

| , B − ∑[\]^ ∈_ Z

| , W > ∑[\]^ ∈_ Z

&
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Proof of Proposition 1.
We prove proposition 1 by induction based on the case
similar. For t =100, - 0jj

≤ - 1jj

= : . The proofs for cases

holds because - jj

Let
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= 0.

≠ : are

Z P, B = ( P, B + ∑[&

∈_ Z &

Z W, B = ( P, W + ∑[&

∈_ Z &

%

&
&

&

%

|P, B ,
&

|P, W ,

% NP|P, B = % P|P, B + %k P|P, B , and
% T|P, B = : :l |:, m + : nl |:, m + : :o |:, m + : no |:, m + : 6|:, m
+ : 3|:, m .

0
Given any t = T and -k&

1
≤ -k&

, we need to prove -k0

k

≤ -k1

k

.

Using assumption 2,

vpq P, B − vpr P, B
= M rp P, B + Vpq NP, B pqp NP|P, B + Vpq T, B Ppq T|P, B
+ Vpq D pqp D|P, B N
− M rp P, B + Vpr NP, B prp NP|P, B + Vpr T, B Ppr T|P, B
+ Vpr D prp D|P, B N
= Vpq NP, B pqp NP|P, B − Vpr NP, B prp NP|P, B + Vpq T, B Ppq T|P, B
− Vpr T, B Ppr T|P, B + Vpq D pqp D|P, B − Vpr D prp D|P, B

According to Vpq sp ≤ Vpr sp , we have

Vpq NP, B ≤ Vpr NP, B , Vpq T, B ≤ Vpr T, B , and Vpq D = Vpr D

Using assumption 1, we have

pqp NP|P, B ≤ prp NP|P, B , pqp T|P, B ≥ prp T|P, B , and pqp D|P, B ≥ prp D|P, B
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∴ vpq P, B − vpr P, B
≤ Vpr NP, B Mpqp NP|P, B − prp NP|P, B N
+ Vpr T, B Mpqp T|P, B − prp T|P, B N + Vpr D Mpqp D|P, B − prp D|P, B N
≤ Vpr NP, B Mpqp NP|P, B − prp NP|P, B + pqp T|P, B − prp T|P, B
+ pqp D|P, B − prp D|P, B N = Vpr NP, B 1 − 1 = 0
Let

V NP, W = V N

P P|P, W
P N|P, W
+ V P
P N|P, W + P P|P, W
P N|P, W + P P|P, W

According to Vpq sp ≤ Vpr sp , we have Vpq NP, W ≤ Vpr NP, W
According to assumption 1, we have

pqp NP|P, W ≤ prp NP|P, W , and pqp D|P, W ≥ prp D|P, W
∴ vpq P, W − vpr P, W

= Vpq NP, W pqp NP|P, W − Vpr NP, W prp NP|P, W + Vpq D pqp D|P, W

− Vpr D prp D|P, W

≤ Vpr NP, W Mpqp NP|P, W − prp NP|P, W N
+ Vpr D Mpqp D|P, W − prp D|P, W N
≤ Vpr NP, W Mpqp NP|P, W − prp NP|P, W + pqp D|P, W − prp D|P, W N

∴ -k0

= Vpr NP, W 1 − 1 = 0

= maxt vpq P, B , vpq P, W u ≤ maxt vpr P, B , vpr P, W u = -k1

Proof of Proposition 2.
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.

We prove proposition 2 based on the case

= : . The proofs for cases

v P, B − v 4 P, B = M rv P, B + ∑[\]^ ∈wxy Z
M rv P, B + ∑[\]^ ∈wxy Z

&

v P, W − v 4 P, W = 0;

∴-

&

%

= max vv P, B , vv P, W

&

&

&

%

&

|P, B + * 4& 3 N = *

|P, B + *
&

≥ max vv4 P, B , vv4 P, W

Proof of Corollary 1.
The proof is similar to that of proposition 2.
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≠ : are similar.
3 N−

&

3 − * 4& 3 ≥ 0 ;
= -4

.

3 Adaptive Decision-Making of Breast Cancer Mammography Screening: A HeuristicBased Regression Model

Abstract
The American Cancer Society (ACS) updated their breast cancer screening guidelines in late
2015 and recommends that all women have the choice to start annual mammography screenings
beginning at age 40. For women ages 45 to 54, the ACS explicitly recommends annual
mammograms. However, due to the potential harms associated with screening mammography,
such as overdiagnosis and unnecessary work-ups, the best strategy to design an appropriate
breast cancer mammography screening schedule remains controversial. Instead of recommending
a one-size-fits-all screening schedule, this study identifies a personalized mammography
screening strategy adaptive to each woman’s age-specific breast cancer risk. We present a twostage decision framework: (1) age-specific breast cancer risk estimation, and (2) annual
mammography screening decision-making based on estimated risk. The results suggest that the
optimal combinations of independent variables used in risk estimation are not the same across
age groups. Our optimal decision models outperform the existing mammography screening
guidelines in terms of the average loss of life expectancy. While most earlier studies improved
the breast cancer screening decisions by offering lifetime screening schedules, our proposed
model provides an adaptive screening decision aid by age. Since whether or not a woman should
receive a mammogram is determined based on her breast cancer risk at her current age, our “online” screening policy adapts to a woman’s latest health status, which reflects the current
individual risk of each woman more accurately.
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3.1. Introduction
Breast cancer is the most common non-skin cancer among U.S. women. According to the
American Cancer Society (ACS), an estimated 246,660 women will be diagnosed with breast
cancer, and an estimated 40,450 women will die from this disease in 2016 (ACS 2016). Routine
screening mammography may reduce mortality from breast cancer by detecting the disease at
early stages, before the cancer has spread. Several clinical trials and population-based
evaluations suggest that mammography may reduce breast cancer mortality significantly (Tabar
et al. 2003, Weedon-Fekjær et al. 2014).
Nevertheless, there are potential harms associated with screening mammography, such as
overdiagnosis, exposure to radiation, and work-up of positive findings. A cohort study by
Hubbard et al. (2011) reported that after ten years of annual screenings, over half of participating
women will receive at least one false-positive result. The high false-positive rate of screening
mammography (i.e., the mammogram is interpreted as positive but no cancer is present) often
results in unnecessary follow-up imaging and biopsy exams, which rule in or out the presence of
breast cancer after a positive test result. As an invasive procedure, a biopsy may place a woman
at risk of morbidity and, in rare cases, mortality (Bruening et al. 2009). The proportion of women
with abnormal mammography findings that are diagnosed with breast cancer is less than 10%
(Rosenberg et al. 2006).
Due to the significant benefits and harms associated with screening mammography, designing
the most efficient breast cancer screening guideline that maximizes the benefit and minimizes the
harms remains controversial in the public health community (Nelson 2010, Tarnay 2012). The
ACS updated their breast cancer screening guidelines in late 2015 and now recommends that
women begin annual breast cancer screenings beginning at age 45. The guidelines also
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recommend that a woman when reaching age 55 should either switch to biennial screenings or
continue annual mammography. In addition, the American College of Radiology (ACR)
recommends all women begin annual mammography at the age of 40, while the U.S. Preventive
Services Task Force (USPSTF) and the American College of Physicians (ACP) advocate
beginning screening mammography at age 50 and doing so on a biennial basis (Nelson 2010). In
addition, the age at which to cease mammography screening is also debated. Although the ACS
and ACR do not specify the age to stop routine screening mammography, the USPSTF and ACP
recommend against routine screening for women 75 years or older. Furthermore, there are
ongoing discussions on screening frequency and whether it is necessary to perform annual or
biennial screening.
The ongoing debate surrounding screening mammography guidelines motivates researchers to
pursue a decision policy that finds the optimal trade-offs between the negative effects of
screening and patients’ long-term benefits of early diagnosis of breast cancer. Kirch and Klein
(1974) designed a mathematical model to determine the frequency of mammography screening
that minimizes the detection delay for the general population. Their model assumed perfect
mammography screening sensitivity and specificity, but in fact, the actual false positive rate of
mammography is high. Some additional studies, such as Ozekici and Pliska (1991) and Zelen
(1993), considered false positives and false negatives of screening mammography exams in their
mathematical models. However, the parameters used in these models were not age-specific,
making their solutions less practical since breast cancer risk increases with age. According to
Gail and Rimer (1998), an appropriate screening recommendation should reflect each woman’s
individual risk. Since each woman has different levels of breast cancer risk based on her personal
risk factors, breast cancer screening schedules should not be uniform across women. Several
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more recent studies addressed this issue by including age- and patient-specific input parameters
and generated some effective optimization models for mammography screening policies. Maillart
et al. (2008) employed a partially observable Markov process model considering women’s age
and menopausal status to evaluate different screening mammography policies. Their model used
different stages of breast cancer as core states and generated a set of efficient policies in terms of
life-time breast cancer mortality and the expected total number of screening mammograms.
Chhatwal et al. (2010) focused on how to make biopsy referral decisions after positive screening
mammograms to maximize patients total expected quality-adjusted life years (QALYs). They
developed a finite-horizon discrete-time Markov decision process (MDP) model to offer optimal
biopsy referral policies for patients with different breast cancer risk scores (i.e., a woman’s
current probability of cancer based on her risk factors and mammographic features). Ayvaci et al.
(2012) applied an MDP model to optimize biopsy referral decisions for different breast cancer
risk scores under budgetary restrictions. The model by Ayer et al. (2012) is the first screening
decision study that directly personalizes mammography screening. They developed a partially
observable Markov decision process (POMDP) model that offers optimal screening
mammography schedules based on five personal risk factors: age, race, age at menarche, age at
first birth and prior screening history. Moreover, similar modeling approaches have also been
applied to the screening decisions of some other cancers, such as prostate cancer. Zhang et al.
(2012) developed a POMDP to determine optimal biopsy referral decisions for prostate cancer
screening based on prostate-specific antigen tests. Erenay et al.’s POMDP model optimized
colonoscopy screening policies for colorectal cancer (2014). Besides age, Erenay et al.’s
personalized model incorporated both static (i.e., gender) and dynamic factors (i.e., history of
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colorectal cancer and polyp). In particular, Alagoz et al. (2011) provided an overall review
regarding the applications of various operations research models in cancer screening.
Most of these previous studies utilized Markov modeling approaches, which are inefficient in
solving problems with high computational complexity. Since incorporating additional breast
cancer risk factors into the model leads to a higher dimensionality of the decision-making
framework, a Markov model will inevitably suffer from the so-called curse of dimensionality
(Bellman), which refers to the computational complexity that grows exponentially with the
dimensionality. Incorporating too many risk factors could cause a Markov model to be
computationally intractable. In addition, since all states and transition probabilities between
states in Markov models must be precisely pre-specified, it is difficult for these models to
process some dynamic risk factors, such as a woman’s body mass index (BMI), which are
fluctuating over time and thus unpredictable. Hence, these prior studies mainly focused on
optimal static lifetime screening policies such that optimal decisions cannot be updated
dynamically or adjusted with unpredictable new information.
Our study aims to circumvent the limitations of traditional Markov modeling approaches on
this topic by proposing a two-stage individualized mammography screening decision framework
that is adaptive to changes in risk factors. We first perform a heuristic-based regression analysis
with model selection to evaluate a woman’s probability of breast cancer at her current age based
on a range of personal risk factors. Then we determine whether this woman should undergo a
screening mammogram based on her estimated breast cancer risk at her current age.
Advances in health informatics and analytics in recent years have improved health prediction
and management for chronic diseases (West et al. 2005, Misiunas et al. 2016, Bertsimas et al.
2016). In this study, we not only take advantage of logistic regression to eschew the curse of
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dimensionality of Markov models, but also discuss the dimensionality reduction of regression
models in the context of medical decision-making. We design a novel model selection method
for logistic regression from the perspective of making optimal screening decisions. The
optimality of a decision is defined in terms of minimal misclassification cost (i.e., the cost of
false positives and false negatives), which is a critical concern in medical practice.
The remainder of the paper proceeds as follows: in Section 3.2, we describe the decisionmaking framework. We then present the numerical results by implementing the model in Section
3.3. In Section 3.4, we discuss the results and their significance to the decision-making of breast
cancer mammography screening as well as other disease prevention and treatment problems.

3.2. Methods
In this study, the decision-making process consists of two sub-models: breast cancer risk
estimation and decision-making of mammography screening utilization based on the estimated
risk. The risk estimation model is a regression model used to predict a woman’s probability of
developing breast cancer at her current age based on a number of breast cancer risk factors. The
risk estimation model is built based on the predictors from the widely accepted Barlow model
(Barlow et al. 2006). We improve their model by conducting a model selection with the aim of
increasing life expectancy, which is impacted by the false-positive and false-negative prediction
errors. According to the estimated probability of developing breast cancer, the next sub-model
determines whether this woman should be referred for a screening mammogram or if she should
skip the mammogram in the current year and return for screening the following year. In this submodel, a pre-specified optimal cut-off point of cancer probabilities, which is expected to
minimize the woman’s loss of life expectancy, serves as a threshold of recommending a
screening mammogram. Therefore, the decision-making framework works in an adaptive manner
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such that it allows women to input their current risk factor levels, and then the framework
generates corresponding optimal decisions regarding mammography screening.

3.2.1. Breast Cancer Risk Estimation Model
The probabilities of breast cancer for women with various risk factors are estimated using a
logistic regression model. We formulate the regression model based on the results from the
Barlow breast cancer risk model (Barlow et al.2006). The breast cancer risk factors identified in
the Barlow model includes age (by 5-year age groups), race (white, black, Asian, native
American, and other), Hispanic ethnicity (year/no), number of first degree relatives with breast
cancer (0, 1, and 2 or more), age at first birth (<30, >=30, and nulliparous), surgical menopause
(yes/no), use of hormone replacement therapy (yes/no), menopausal status
(premenopausal/postmenopausal), body mass index (10-25, 25-30, 30-35, and 35 or more),
previous breast procedure (yes/no), and last mammographic outcome (positive/negative).
However, a number of prior studies revealed that breast cancer risk factors are not independent.
Mayberry and Stoddard-Wright (1992) reported that the effects of some breast risk factors on
women of different races are not the same, such as family history and age at menarche. For
instance, they found that black women who have first-degree relatives and second-degree
relatives with breast cancer have similar relative risks of breast cancer, while for white women
having first-degree relatives with breast cancer leads to higher relative risk compared to only
having second-degree relatives with breast cancer. Cleary and Maihle (1997) reported an inverse
association between BMI and the relative risk (RR) of developing breast cancer in
premenopausal women, but a positive association in post-menopausal women. Some studies
showed that breast cancer risk patterns vary by age and menopausal status (Clavel-Chapelon and
Gerber 2002). These studies suggest the existence of interaction effects between the 11 risk
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factors described above. Therefore, we consider all possible two-way interaction terms in the
regression analysis to more accurately estimate woman’s breast cancer risk. The binary response
variable is defined by whether a woman has breast cancer in the current year.
A regression model that includes all explanatory variables with interaction terms may lead to
overfitting and thereby have poor predictive power (Wears and Lewis 1999). In addition,
although all of the 11 risk factors have been associated with breast cancer risk, not all of them
may be instrumental for finding the optimal decision of mammography screening at every age
based on the prediction of breast cancer risk. Thus, a model selection procedure aimed to reduce
dimensionality of explanatory variables and find the optimal regression model is necessary.
Two components are essential to model selection: a criterion or a benchmark for comparing
different models and a search strategy for selecting variables. While a criterion serves as a cost
function that measures whether a subset of the variables available produces the best model, a
search strategy specifies the course of evaluating each subset of explanatory variables according
to the criterion.

3.2.1.1. H Measure
There are many traditional model selection criteria in the literature, such as the Akaike
information criterion (AIC), the Bayesian information criterion (BIC), the R4 , the adjusted R4 ,

and the Mallow’s Cz (Kadane and Lazar 2004). In medical applications, however, the

performance of binary classification that determines whether a predicted probability of a specific
disease should be assigned to an abnormal group (also known as positive) or a normal group
(also known as negative) is of special interest to medical decision makers. The receiver operating
characteristic (ROC) analysis, which plots the true positive rate versus the false positive rate at
various threshold settings (from 0 to 100%), is widely adopted for model selection in the medical

62

literature (Rosset 2004). Specifically, the area under the curve (AUC) of a ROC curve provides a
direct measure to compare models. Nevertheless, a fundamental weakness of the AUC measure
is that it assigns two types of error (i.e., false positive and false negative) with the same weights.
Neither the AUC nor other traditional criteria pay attention to the relative severity between the
two types of errors in prediction and classification models. Thus, their model selection outcomes
may be undesired or even unacceptable, especially for some prediction or classification models
used to study life-threatening diseases. For the above reasons, this study applies a recently
developed statistic, called the H measure (Hand 2009, 2010), as a criterion for model selection.
The H measure introduces the notion of misclassification costs by quantifying the relative
severity between the two types of errors. Let { denote a specified threshold, then the following
logic is used to classify a probability output by the breast cancer prediction model as class 1
(cancerous) or class 0 (non-cancerous):

| } =~

1,
0,

if % } > {
,
otherwise

(1)

where } is the vector of explanatory variables; % } is a predicted probability; and | } is the
final prediction that whether a woman has breast cancer or not. We normalize the two types of
misclassification costs by scaling their numeric values in the range of f0,1h. Let • in f0,1h denote

the relative cost of misclassifying a non-cancerous observation as cancer, and thereby 1 − •

represents the relative cost of misclassifying a cancerous observation as non-cancerous. Then the
misclassification cost function of the regression model with given • and { is defined as follows:

•, { = •‚j I1 − Sp { J + 1 − • ‚ I1 − Se { J,

where Sp { is the specificity (i.e., the probability of class 0 observations that are correctly

(2)

identified as class 0) when the threshold is set to {; Se { is the sensitivity (i.e., the probability of

class 1 observations that are correctly classified as class 1) when the threshold is set to {; and
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‚„ , … = 0,1 is the proportion of class i in all observations. In the current study, Se { and Sp {
can be deemed the true positive rates and the true negative rates, respectively. Then we define
the minimum weighted cost (MWC) under the cost • as follows,

MWC • = min
†

•, { .

(3)

Thus, the minimum weighted cost is reached when finding the optimal threshold {‡ :

{‡ = argmin
†

•, { .

(4)

Instead of using a constant cost, the H measure specifies a distribution, ˆ • , to reflect the

uncertainty about the exact value of the cost • . Beta distribution with shape parameters α = β = 2
is usually adopted to represent the cost distribution (Hand 2010). Therefore, the average MWC
(Lg ) of the breast cancer prediction model is calculated by

Lg = ‰
‡

•, {‡ ˆ • )• .

(5)

It is desirable for an index to take larger values for better performance, and ranges between 0
for the worst classification and 1 for perfect classification. Thus, the H measure is defined as

H=1−

Lg
,
LŒ•Ž
‹

(6)

where LŒ•Ž
‹ is a constant equal to the maximum value that Lg can reach, which means a trivial
classifier is employed to make random classification (i.e., the false positive rate is always
identical to the true positive rate).
We calculate the H measure for each candidate prediction model, which is a regression
polynomial composed of a non-null subset of the explanatory variables. Hence, the optimal
prediction model is the one with the highest H measure.
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3.2.1.2. Misclassification Cost
The calculation of the H measure is based on well-defined misclassification costs. In this study,
the cost • (the misclassification cost of a false positive result) is defined as the reduction in life
expectancy if a woman without breast cancer is classified into the group with an increased risk of
cancer and recommended to undergo a screening mammogram exam. The cost 1 − • (the
misclassification cost of a false negative result) corresponds to the loss of life expectancy when a
woman with breast cancer is classified into the group with a low risk of cancer and
recommended to skip a screening mammogram. The Breast Imaging Reporting and Data System
(BI-RADS) of the ACR, a lexicon used by radiologists for mammography interpretation,
describes the level of cancer suspicion for the exam (Sickles et al. 2013). Radiologists interpret
and assign screening mammograms into one of the seven BI-RADS assessment categories
(D’Orsi et al. 2013). BI-RADS 0 is considered an incomplete mammogram that requires
additional imaging. BI-RADS 1 and 2 are associated with negative or benign findings. BI-RADS
3 is a probably benign finding, which needs short interval follow-up. BI-RADS 4 is suspicious
abnormality, and BI-RADS 5 is highly suggestive of malignancy. Patients with either BI-RADS
4 or 5 are recommended to undergo an immediate biopsy. BI-RADS 6 is used for biopsy proven
breast cancers. In this study, we define a positive screening mammogram as those with a BIRADS score of 0, 4 or 5. We assume BI-RADS 0 is always followed up by a diagnostic
mammogram. We also assume that if a diagnostic mammogram is suspicious (BI-RADS 4 or 5),
then a biopsy is recommended. Thus, mammograms that are finally classified as BI-RADS 4 or 5
result in biopsy referrals. The cost c includes the disutilities (i.e., reduction in life expectancy) of
an initial screening mammogram, a possible diagnostic mammogram and a possible follow-up
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biopsy. Let • • denote the unscaled value of • at age , then • • represents the cost of a false
positive decision for a woman at age :

• • = ) ‘ + P Bj |NC ∙ ) ‘ + P Positive|NC ∙ ) 1 ,

(7)

where ) M and ) B are the disutilities (in years) of a mammogram (both screening and diagnostic)
and a biopsy at age , respectively; : Bj |NC is the probability that a healthy woman’s

screening mammogram is labeled as BI-RADS 0; and : Positive|NC is the probability that a
mammogram is finally assigned to BI-RADS 4 or 5 for a healthy woman without breast cancer.
The misclassification cost of a false negative result is the loss of life expectancy caused by
skipping a screening mammogram, which would have detected a cancer for a woman with breast
cancer. Let • “ denote the unscaled value of 1 − • at age . The misclassification cost of a false
negative result is equal to the difference between the life expectancy of skipping a necessary
screening mammogram (

w”

) and undergoing a necessary screening mammogram (

•”

) for a

woman with breast cancer:

•“ =

•”

−

w”

,

(8)

We consider the cost of skipping one necessary screening mammogram (i.e. a mammogram
for a woman with cancer) as the loss of life expectancy due to at least a one-year delay in
diagnosis and treatment of breast cancer. For a breast cancer patient, such a loss involves two
possibilities: (1) an untreated in situ cancer progresses to an invasive cancer; (2) an untreated
invasive cancer patient dies from breast cancer. According to Yen et al. (2003), we can
categorize in situ breast cancers into two types: the non-progressive in situ cancer (insj ), which

has no propensity to progress to an invasive stage; and the progressive in situ cancer (ins ),

which has the possibility to advance. We model the progression from in situ cancer to invasive
cancer as a Poisson process, which is a common assumption used in previous studies (Yen et al,
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2003, Jackson et al, 1981). Therefore, a breast cancer patient who skips a screening mammogram
at age has a life expectancy of:
w”

= : ins|C ∙

w”

ins + : inv|C ∙

w”

inv ,

(9)

where : ins|C and : inv|C are proportions of in situ cancers and invasive cancers among all
breast cancer cases for women at age ;

w”

ins and

w”

inv are life expectancies of in situ

and invasive patients when skipping a necessary screening mammogram, respectively. As in situ
cancers are generally considered not life-threating, we assume an in situ cancer patient will not
w”

die from breast cancer within one year of diagnosis (Ozanne et al. 2011). We calculate

ins

as follows:
w”

ins = : insj|ins f1 +
− ex–\ ∙ f1 +

&
&

insj h + : ins |ins ∙ ex–\ ∙ f1 +

inv h ,

&

ins h + 1 (10)

where : insj |ins and : ins |ins are the proportions of insj and ins in all in situ cancer

cases, respectively; — is the one-year progression rate from ins to invasive cancer;
&

ins , and

&

&

inv are life expectancies of patients with non-progressive in situ,

insj ,

progressive in situ, and invasive cancers at age + 1, respectively. Note that we calculate the
difference of life expectancy between skipping and undergoing a screening mammogram by
subtraction, so the loss of life expectancy due to death from a cause other than breast cancer is a
redundant term appearing in both the minuend and the subtrahend. Thus, we omit the mortality
from other causes in one year and focus on the cancer-specific survival. Similarly, the life
expectancy (

w”

inv ) of an invasive cancer patient who skips a mammogram is:

w”

inv = : UD ∙ 0.5 + f1 − : UD h ∙ f1 +
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&

inv h,

(11)

where P UD represents the breast cancer-specific death rate of an untreated invasive cancer
patient at age . We assume the life expectancy of a treated patient who dies at age to be half
year (Chhatwal et al. 2010).
To derive

•”

, we first consider a breast cancer patient who chooses to undergo a screening

mammogram and successfully detects her breast cancer. Let

™š

denote such a patient’s life

expectancy:
™š

where

= : ins|C ∙ f1 +
&

ins k and

&

&

ins k h + : inv|C ∙ f1 − : D h ∙ f1 +
0.5 ∙ : D ,

&

inv k h +

(12)

inv k are life expectancies of patients treated for in situ cancer and

invasive cancer patients at age + 1, respectively; and : D denotes the one-year death rate of
treated invasive cancer at age .
Taking into account the possible false negative mammogram outcome and the disutility of
screening, we obtain the life expectancy of a breast cancer patient who chooses to undergo a
screening mammogram at age :
•”

= −) ” − P Bj |C ∙ ) ‘ + : Positive|C ∙ I

™š

− ) r J + : Negative|C ∙

w”

,

(13)

where : Bj |C is the probability that a breast cancer patient’s screening mammogram is labeled
as BI-RADS 0; : Positive|C is the probability that a breast cancer patient is referred for a

biopsy, whose screening mammogram or diagnostic mammogram has a BI-RADS score of 4 or
5; and : Negative|C is the probability that a breast cancer patient is not recommended for a
biopsy when either the screening mammogram or the diagnostic mammogram (when necessary)
is classified as BI-RADS 1, 2 or 3. The life expectancy for a woman with biopsy-confirmed
breast cancer is

™š
v

subtracting the disutility of the biopsy, the screening mammogram and the

possible diagnostic mammogram. If a woman is not referred for a biopsy after a screening
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mammogram and/or a diagnostic mammogram, only the disutility of the possible mammograms
needs to be considered in life expectancy calculation.
After normalizing the costs obtained from (7) and (8) to • and 1 − • , we obtain the costs of
two types of misclassification errors for calculating the H measure. As mentioned above, the
costs of the two types of misclassification are both age-specific. Hence, we stratify the optimal
risk estimation model by age.

3.2.1.3. Search Strategy
The H measure is used as a criterion to compare different models and identify the optimal
combination of explanatory variables. The model selection can be considered as an integer
programming problem. In this problem, the H measure is the objective function to be maximized.
The solution space consists of all available explanatory variables and their interaction effects.
Every feasible solution is a binary configuration of explanatory variables and interaction effects,
where values 0 and 1 correspond to being selected and excluded, respectively. Suppose that there
is a dependent variable |, a group of explanatory variables Χ œ and their corresponding

coefficients •„ as well as the intercept •j. Given a sample S composed of a group of observations
of | and ž , ž4 , … , ž , let Hw ∙ denote the H measure function with a sample S. The binary

configuration of every explanatory variable is represented by a binary variable }„ , which

indicates whether the corresponding explanatory variable ž„ is chosen or not. Likewise, every

interaction effect is denoted by ž„ žŸ , controlled by a binary variable }„Ÿ . Then the search

strategy to find the optimal logistic regression model maximizing H measure can be formulated
as a 0-1 integer programming problem as follows,

Maximize Hw Ilogit Pr ||ž , ž4 , … , ž
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J

(14)

where logit Pr ||ž , ž4 … , ž
subject to:

= •j + •„ ¢ ž„ }„ + ¢ •„Ÿ ž„ žŸ }„Ÿ
„

„£Ÿ

}„ = 1 or 0,
}„Ÿ = 1 or 0 .
Solving this 0-1 nonlinear integer programming problem would find the optimal subset of
explanatory variables. Traditionally, some nonlinear integer programming problems can be
solved by linearization techniques, e.g. simple approximation using piecewise linear functions
(Jünger et al. 2009). Considering the complex structure of Hw ∙ and the varying values of the
objective function dependent upon the given sample S, it is obvious to see that the objective
function in (14) cannot be converted to an integer linear programing problem. Thus, it is unable
to solve this 0-1 nonlinear integer programming using existing exact algorithms, such as cutting
plane and branch and bound methods. Although an exhaustive search that examines all non-null
subsets of the explanatory variables can always find the optimal model, such a full-scale search
is often not feasible in practice. In medical studies, regression analyses often involve a large
number of observations, which make exhaustive searches computationally expensive.
Furthermore, the high dimensionality of the explanatory variable space can also result in
intractable computational effort. For example, if we model all the 11 breast cancer risk factors
and all possible two-way interaction effects between them as the explanatory variables, there are
66 variables being considered, which constitute 2©© − 1 non-null subsets in total. Calculating the
H measure for each model and identifying the optimal model is nearly impractical. Therefore, a
suboptimal heuristic search strategy is useful in this case.
In recent years, the most commonly used heuristic search strategy of model selection is the
greedy search algorithm, which is also referred to as stepwise search (Miller 2002). Since a
greedy search usually finds local optima, there are studies using more advanced heuristic
algorithms to avoid the shortcoming of the stepwise search. Yang and Honavar (Yang and
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Honavar 1998) used a genetic algorithm to perform the model selection and received nearoptimal results. Sivagaminathan and Ramakrishnan (2007) developed a hybrid approach of
neural networks and ant colony optimization for model selection. Orkcu (2013) found a
combination of the genetic algorithm and the simulated annealing algorithm outperforms the
original genetic algorithm in most cases.
In this study, aiming at overcoming the local optima of the stepwise model selection methods,
we propose a new model selection method for generalized linear model by combining the tabu
search algorithm with the H measure. Tabu search was originally introduced by Glover (1989) as
an optimization tool applicable to nonlinear covering problems. In various problem settings, tabu
search has produced outcomes equal or superior to the best results previously found by other
algorithms (Fouskakis and Draper 2002). Furthermore, tabu search has been shown to be very
efficient in terms of calculation time in solving many search and optimization problems, even
when compared with some advanced heuristic algorithms, such as genetic algorithm and
simulated annealing (Augugliaro et al. 1999). As our model has a large number of candidate
variables, the calculation time is of great concern. Considering the efficiency and effectiveness
of tabu search, we adopt a modified version of tabu search as the search strategy. The modified
algorithm consists of three phases: preliminary, intensification, and diversification (Fouskakis
and Draper 2002, Glover 1990). In the first phase, this algorithm works as the original tabu
search. The preliminary search continues for a specified number of iterations. When it reaches
the upper limit of iterations, it moves on to the intensification phase. The intensification starts
with the best solution found thus far and clears the tabu list, and then proceeds as in the
preliminary phase. If a better solution is found, intensification is restarted with the better solution
and an empty tabu list. Such a process repeats until the upper limit of iterations is reached and
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then goes to the diversification stage. Intensification allows the algorithm to focus the search
around the current best solution. The last phase, diversification, provides a way to explore spaces
that have not been visited in the first two phases. The diversification clears the tabu list and sets
the most frequent moves as tabu. Then the algorithm starts with a random solution and proceeds
as in the preliminary phase. After going through the three phases, the model with the highest H
measure found in the whole process is reported as the optimal breast cancer risk estimation
model. A detailed algorithm is described in Figure 1.

Tabu Search Model Selection Algorithm
1. Specify the size of the tabu list s and the number of iterations n.
2. Fit a model using all variables and use the one with the highest absolute multiplier as initial
solution.
3. Evaluate the solution (by calculating the corresponding H measure).
Preliminary Phase
Repeat
(1) Change the solution by removing or adding a variable (switch the value of variable
between 0 and 1).
(2) If the objective value > the aspiration value i.e., the best solution so far, then accept it
as the current solution.
Else if the element is in the tabu list, then go to the neighboring variable.
Else if the element is not in the tabu list, then accept it as the current solution.
(3) Update the tabu list and the aspiration value.
(4) Check stopping criterion.
If the iterations reach the upper limit n, record the best solution X so far and go to the
intensification phase.
Intensification Phase
Start with the best solution X so far and clear the tabu list.
Repeat
Do the preliminary phase, until a solution better than X is found and restart the
intensification phase.
If the number of iteration reaches n, go to the diversification phase.
Diversification Phase
(1) Clear the tabu list and set the s most frequent moves as tabu.
(2) Randomly generate a solution.
Repeat
Do the preliminary phase, until the number of iteration reaches the upper limit n.
Report the best solution found in the three phases.
Figure 1 The model selection algorithm
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It is known that, in order for an interaction effect to be significant, at least one of its
constituent main effects should be significant under the so-called effect heredity principle (Wu
and Hamada 2011). However, since the purpose of the modeling focuses on the predictive
performance of each model under the imbalanced misclassification costs, rather than its
conventional statistical interpretability, our model selection procedure still allows an interaction
effect to be selected without its constituent main effects, which is consistent with the majority of
other model selection methods (Cleves 2008, Shmueli 2010, Lenz et al. 2012).

3.2.2. Decision Rule of Accepting or Rejecting a Screening Mammography Exam
After the optimal risk estimation model is identified, the second stage of the decision-making
framework is to determine whether a woman should undergo a screening mammogram in the
current year based on her estimated breast cancer risk. We adopt the misclassification cost term
criterion (MCT) (Greiner 1996) to calculate the optimal cut-off points of cancer probabilities for
recommending a screening mammogram. The MCT is a variant of Equation (4). It also
incorporates the costs associated with false-positive and false-negative misclassifications to
determine the optimal threshold that results in the least expected cost. Let ∅ denote the optimal
cut-off point at age . Only when a woman has a breast cancer risk higher than the optimal cutoff point, should she be recommended to undergo a screening mammogram at the current age.
Based on the MCT, the optimal cut-off point for age t, ∅ , is determined by
min

∅\ ∈fj, jj%h

MCT =

•“
∙ % ∙ f1 − Se ∅ h + 1 − % ∙ f1 − Sp ∅ h,
••

where % is the prevalence of breast cancer in age group ; Se ∅

(15)

is the sensitivity associated

with ∅ (i.e., the percentage of true positive decisions in all positive classifications); Sp ∅

is

the specificity associated with ∅ (i.e., the percentage of true negative decisions in all negative
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decisions). Since all parameters involved above are age-specific, we provide the optimal cut-off
point for each age group separately.

3.3. Numerical Study
3.3.1. Data and Parameters Estimation
We use the Breast Cancer Surveillance Consortium (BCSC) dataset (Barlow 2006), which
includes screening mammography information from 1,007,600 women from January 2000 to
December 2009, to execute the regression analysis. The BCSC is a collaborative network of
seven mammography registries for studies aiming to assess the delivery and quality of breast
cancer screening and related patient outcomes in the United States (2004). Each woman in the
BCSC dataset has one screening mammogram and corresponding one-year outcome. The dataset
includes each participants’ breast cancer diagnosis information within 1 year of the screening
mammogram as well as their personal characteristics (including risk factors) as introduced in
Section 3.2.1. All these risk factors, except age, are incorporated as explanatory variables in the
regression analysis of the risk model. Age is used to stratify the regression models so as to
provide age-specific risk estimation models and cut-off points. We adopt the listwise deletion to
deal with missing data. In this numerical study, we consider women aged 40-84 since the BCSC
data only includes women aged 84 and younger. Whether the woman is diagnosed with breast
cancer within one year of the screening mammogram serves as the response variable. We also
use this dataset to derive the age-specific prevalence of breast cancer (: ), as well as the

proportions of in situ cancer (: ins|C ) and invasive cancer cases (: inv|C ).

In order to validate the performance of our decision model, we use the holdout method that
randomly splits the dataset into a training set and a test set. The training set contains 70% of the
observations, while the remaining 30% are used to build the test set. We use the training set to fit
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regression models and determine optimal cut-off points. Then the test set is employed to validate
our decision model and make comparisons with alternative mammography screening
recommendations.

Table 1 Sources of data input for model parameter estimation
Parameters
— , P insj|ins , P ins |ins ,
)”, )r
: D , : UD
inv p ,
insp ,
insj
: Positive|NC , : Negative|C ,
: Positive|C
P Bj|NC , : Bj|C
ins ,

inv ,

Source

Yen et al. (2003)
Saarni et al. (2006); Ayer et al., (2012)
Verkooijen et al. (2005); Zhang (2011)
Beck et al. (1982)
Arias (2011); Howlader et al. (2012)
Yankaskas et al. (2005); Weaver et al. (2006)
Hubbard et al. (2011)
BCSC (2009); Zhang (2011); Arias (2011); Yen et al.
(2003)

Table 1 lists other parameters used in the numerical experiments. In particular, as a woman
ages, the risk and side-effects caused by a biopsy become more serious (Burnside et al. 2012).
Hence, we assume the disutility of biopsy is inversely proportional to the age-specific EQ-5D
scores of the general population (Saarni et al. 2006), which reflects the varying negative impacts
of biopsy on women’s health at different ages. Since no study provides age-specific annual death
rates of untreated invasive breast cancer, we estimate these rates based on the one-year treated
death rate of invasive cancer using the data from an earlier study (Zhang 2011). To adjust for the
untreated breast cancer, we use Verkooijen et al.’s finding (2005) on the effect of refusal of
treatment on mortality, i.e., the death rate of untreated breast cancers is threefold higher than that
of treated breast cancers. In addition, we assume that life expectancy of patients treated for in
situ cancer (

ins p ) is equal to that of the general population, since the survival rate of in situ

cancer is nearly 100% (Recht et al. 1998). Similarly, as a non-progressive in situ cancer will
never progress to a life-threating invasive disease even if left untreated (Yen et al. 2003), we also
assume the life expectancy of a non-progressive in situ cancer patient
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insj

to be equal to

that of the general population. We calculate the life expectancy of patients treated for invasive
cancer (

inv p ) using the DEALE method based on the 10-year survival of invasive breast

cancer (Beck et a. 1982, Howlader et al. 2012).

… Z

… Z

…

…

Death

Death

k

… Zk

The Markov chain representing progressive
The Markov chain representing
in situ cancer
progression of invasive cancer
p
ins = undetected progressive in situ cancer; ins = in situ cancer patient in treatment;
inv = undetected invasive cancer; inv p = treated invasive cancer;
Death = all-cause death

Figure 2 Markov chain diagrams for estimating
In order to estimate

ins

and

ins

and

inv

inv , we assume that the two types of breast cancer

patients will strictly undergo annual screening mammography from . We use two discrete-time
Markov chain models to estimate their expected values. Figure 2 shows the respective transition
diagrams of the Markov chain models. The transitions from ins and inv to their corresponding

treatment states (ins p and inv p ) are defined as true positive rate of mammography. Thus, a selfloop means the mammogram in the current year fail to detect the in situ cancer or invasive
cancer. The transition from ins to “Death” represents the one-year all-cause mortality rate. The

transitions between ins and inv represents the one-year progression from in situ cancer to

invasive cancer. The treatments and death states are all absorbing states. We assume age 100 is
the end of the time horizon, so there are 100 − steps for a process starting with a state at age .
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Thus, the expected lengths of survival counted during the Markov chains looping from age to
age 100 can be used to estimate the life expectancy of

ins

inv .

and
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Misclassification cost ratio
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3.3.2. Data Smoothing

40
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70
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Age

Figure 3 Monotonic transformation of the cost ratios
Braithwaite et al. (Braithwaite et al. 2013) found frequent screenings result in higher risk of false
positive mammography results and biopsy referrals without added benefit on older women as
compared with younger women. Therefore, it is reasonable to assume that, the ratio between the
cost of a false negative result and the cost of a false positive result, which reflects the net benefit
of undergoing a mammography screening, will decrease as women age. While the calculated
results of the cost ratios by age show a decreasing trend (dots in Figure 3), they are not
monotonically decreasing. This may be due to various sources of input data for numerical
calculation. In this study, we use a monotone smoothing method proposed by Ramsay (1998) to
regularize the raw results of the cost ratios so that they are monotonically decreasing with age.
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Suppose }j is the lower boundary of age, and the monotonically increasing smoothing function
is defined as follows.
°

¬ } = •j + • ‰ e- ® d ¯ ,

(16)

°±

where •j is the value of ¬ }j ; β1 is the slope of ¬ } at }j ; and w ¯ is a B-spline basis
function of order 6 with w }j equal to zero. •j , • and w ¯ are three objects for each

smoothed curve estimated from the raw results. The smoothing function iteratively minimizes
the least squares fitting criterion (see Ramsay (1998) for details). The monotonically smoothed
results of the cost ratios are plotted in Figure 3 with a solid line.

3.3.3. Results
Table 2 Parameters of the tabu search
Size of the tabu list
Iterations in each phase
Total iterations in three phases

5
100
300

10
500
1500

20
1000
3000

We set several scenarios to execute the tabu search algorithm for each age group. Table 2
summarizes the size of the tabu list and the number of iterations in each phase for each scenario.
We use three typical levels of total iterations, which represent small, medium and large iteration
numbers to test the convergence of the tabu search algorithm. In addition, three different tabu list
sizes are employed to ensure a better performance. Therefore, for each age, the model selection
is performed 9 times. The best results in 9 runs are selected as the optimal prediction models.
We found the choice of the size of tabu list does not affect the final solutions (results not
shown). However, for most age groups, only when the number of iterations in each phase is set
to be higher than or equal to 500, does the iteration procedures converge to their final solutions.
In contrast, when it is set to 100, the iteration process rarely converges but usually keeps finding
better solutions until the end of the intensification phase or the diversification phase. Table 3
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shows the combination of explanatory variables of each age’s optimal risk prediction model as
well as its corresponding value of the H measure.
Although all of the risk factors we included have been associated with increased breast cancer
risk in previous studies, the main effects included in the prediction model vary dramatically with
age. The main effect selected most often is last mammographic result, which is included in 28
out of 45 age groups. In contrast, the main effect selected least often is current menopausal
status, which never appears as a main effect. In addition, as expected, the interaction effects
between different risk factors play a vital role in every model. Since we allow our model
selection to select an interaction effect without its constituent main effects, some risk factors,
which form the principal part of interaction effects of a model, do not appear in the main effects
of the model. For example, in the risk model of age 40, although BMI and previous breast
procedure are not selected as main effects, they are involved in 8 different interaction effects
(i.e., race×bmi, bmi×agefirst, bmi×nrelbc, bmi×brstproc, bmi×lastmamm, race×brstproc,
hispanic×brstproc, and brstproc×lastmamm). Such a pattern is very common in other age groups.
In particular, although menopausal status never serves as a main effect, it is included in the
interaction effects of all age groups between 45 and 54 years. In addition to menopausal status,
we also found some risk factors are much more common in the interaction effects than in the
main effects, such as the number of first degree relatives with breast cancer. While this factor is
the second least selected main effect and only appears in 14 age groups as the main effect (ages
40-44, 47-49, 62, and 80-84), it appears in the interaction effects of 44 out of 45 age groups.
These results imply menopausal status and the number of first degree relatives with breast cancer
are akin to cofactors that join with another factor to affect a woman’s breast cancer risk.
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Table 3 Risk estimation models and cut-off probabilities for accepting a mammogram
Age
menopaus
race
hispanic
bmi
agefirst
Main
effects
nrelbc
brstproc
lastmamm
surgmeno
hrt
menopaus×race
menopaus×hispanic
menopaus×bmi
menopaus×agefirst
menopaus×nrelbc
menopaus×brstproc
menopaus×surgmeno
menopaus×lastmamm
menopaus×hrt
race×hispanic
race×bmi
race×agefirst
race×nrelbc
race×brstproc
race×lastmamm
race×surgmeno
race×hrt
hispanic×bmi
hispanic×agefirst
hispanic×nrelbc
hispanic×brstproc
hispanic×lastmamm
Interaction
hispanic×surgmeno
effects
hispanic×hrt
bmi×agefirst
bmi×nrelbc
bmi×brstproc
bmi×lastmamm
bmi×surgmeno
bmi×hrt
agefirst×nrelbc
agefirst×brstproc
agefirst×lastmamm
agefirst×surgmeno
agefirst×hrt
nrelbc×brstproc
nrelbc×lastmamm
nrelbc×surgmeno
nrelbc×hrt
brstproc×lastmamm
brstproc×surgmeno
brstproc×hrt
lastmamm×surgmeno
lastmamm×hrt
surgmeno×hrt
H measure
Ratio between • “ and • •
Optimal Cut-off point (‰)

40

41

42

43

44

√
√

√
√

√
√

√

√

√
√

√
√

√
√

√
√

√
√

√

√

√

√

√

45

46

47

48

49

50

51

52

53

54

√

√

√

√

√

√

√
√

√

√

√

√

√

√

√

√
√

√

√

√

√

√
√
√

√
√
√

√

√

√

√
√
√

√

√

√
√

√

√

√

√

√

√

√

√

√
√

√

√

√

√

√
√
√

√
√

√
√

√
√

√
√
√

√

√
√
√

√
√
√
√
√
√
√
√

√
√
√
√
√
√
√
√

√
√

√
√

√
√
√
√

√
√

√
√
√
√

√
√
√

√
√
√

√
√
√

√

√
√
√

√
√
√
√
√

√
√
√
√
√

√

√

√
√
√

√
√
√

√
√
√

√
√
√

√
√

√
√

√

√

√
√

√
√

√
√

√
√
√

√
√
√

√
√
√

√
√

√
√
√
√

√

√

√
√

√
√
√
√

√

√

√
√

√
√
√
√

√

√

√
√
√
√
√
√

√
√

√
√
√
√

√

√

√
√
√
√
√
√

√
√

√
√
√
√

√

√

√
√

√
√

√
√
√

√
√
√

√
√
√

√
√
√

√
√

√
√

√
√

√
√

√
√

√
√
√

√
√
√

√
√
√

√
√
√
√

√
√
√
√

√
√
√
√

√
√

√
√

√
√

√

√

√

√
√

√
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√
√

√

√

√

√

√

√

√

√

√
√

√
√

√
√

√

√

√

√

√

√

√

√

√
√

√

√

√

√
√
√
√

√

√

√
√
√
√
√

√
√
√
√
√

√
√
√

√
√
√

√
√
√

√

√

√

√
√
√

√
√

√

√

√

√
√
√

√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
√
0.146 0.146 0.147 0.145 0.145 0.240 0.239 0.231 0.231 0.231 0.235 0.228 0.273 0.266 0.266
2023 1993 1933 1900 1893 1890 1881 1850 1817 1808 1803 1789 1739 1705 1700
1.713 1.713 1.713 1.765 1.765 2.201 2.201 2.315 2.315 2.315 2.727 2.845 3.091 3.127 3.127

(Menopaus =menopausal status, Agefirst=age at first birth, Nrelbc=No. of first degree relatives with
breast cancer, Brstproc= Previous breast procedure, Lastmamm= last mammogram, Surgmeno=surgical
menopause, Hrt=current hormone therapy)
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Table 3 Risk estimation models and cut-off probabilities for accepting a mammogram (Cont.)
Age
menopaus
race
hispanic
bmi
agefirst
Main
effects
nrelbc
brstproc
lastmamm
surgmeno
hrt
menopaus×race
menopaus×hispanic
menopaus×bmi
menopaus×agefirst
menopaus×nrelbc
menopaus×brstproc
menopaus×surgmeno
menopaus×lastmamm
menopaus×hrt
race×hispanic
race×bmi
race×agefirst
race×nrelbc
race×brstproc
race×lastmamm
race×surgmeno
race×hrt
hispanic×bmi
hispanic×agefirst
hispanic×nrelbc
hispanic×brstproc
hispanic×lastmamm
Interaction
hispanic×surgmeno
effects
hispanic×hrt
bmi×agefirst
bmi×nrelbc
bmi×brstproc
bmi×lastmamm
bmi×surgmeno
bmi×hrt
agefirst×nrelbc
agefirst×brstproc
agefirst×lastmamm
agefirst×surgmeno
agefirst×hrt
nrelbc×brstproc
nrelbc×lastmamm
nrelbc×surgmeno
nrelbc×hrt
brstproc×lastmamm
brstproc×surgmeno
brstproc×hrt
lastmamm×surgmeno
lastmamm×hrt
surgmeno×hrt
H measure
Ratio between • “ and • •
Optimal Cut-off point (‰)
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56

57

58

59

√

√

√

√
√

√

√

√

√
√

√
√

√
√

√
√

60
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√

√

√

√
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√

√
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√
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√

√

√

√

√

√
√

√
√

√
√
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√
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√

√

√

√

√
√
√
√
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√
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√
√
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√
√

√
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√

√

√

√

√
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√
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√
√
√
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√
√
√
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√
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√
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√
√
√
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√
√

√
√

√
√

√
√

√

√

√

√

√
√
√

√
√
√

√
√
√

√
√
√

√
√
√

√
√
√

√
√

√
√

√

√
√
√

√

√

√

√

√

√
√
√
√
√

√

√
√
√
√
√

√
√
√
√
√

√

√

√

√

√
√

√
√

√
√

√
√

√
√

√
√

√

√

√

√

√
√

√
√

√
√
√
√

√
√
√

√
√
√

√
√
√

√
√

√
√
√

√
√
√

√
√
√
√
√

√
√
√
√
√

√
√
√
√
√

√
√
√
√
√
√
√
√

√

√
√
√
√
√

√
√

√
√

√
√

√
√

√
√
√

√

√
√
√

√

√

√
√
√

√

√

√
√
√

√
√
√

√
√
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√
√

√
√
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√
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√
√
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√
√
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√
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√
√
√

√
√
√

√
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√
√
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√
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√
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√
√
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√
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√
√
√
√
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√
√
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√

√
√

√
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√
√

√
√
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√

√

√

√

√

√

√

√

√
√
√

√

√

√
√
√

√
√
√

√
√

√
√

√
√

√

√
√
√

√
√

√

√
√
√

√

0.230 0.230 0.219 0.243 0.228 0.238 0.226 0.235 0.256 0.241 0.237 0.218 0.221 0.221 0.221
1698 1687 1623 1509 1426 1355 1260 1149 1047 965 898 854 840 839 838
3.524 3.524 3.461 3.761 3.593 3.725 4.523 4.476 4.687 4.729 5.013 5.132 5.132 5.132 5.132
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Table 3 Risk estimation models and cut-off probabilities for accepting a mammogram (Cont.)
Age
menopaus
race
hispanic
bmi
agefirst
Main
effects
nrelbc
brstproc
lastmamm
surgmeno
hrt
menopaus×race
menopaus×hispanic
menopaus×bmi
menopaus×agefirst
menopaus×nrelbc
menopaus×brstproc
menopaus×surgmeno
menopaus×lastmamm
menopaus×hrt
race×hispanic
race×bmi
race×agefirst
race×nrelbc
race×brstproc
race×lastmamm
race×surgmeno
race×hrt
hispanic×bmi
hispanic×agefirst
hispanic×nrelbc
hispanic×brstproc
hispanic×lastmamm
Interaction hispanic×surgmeno
effects
hispanic×hrt
bmi×agefirst
bmi×nrelbc
bmi×brstproc
bmi×lastmamm
bmi×surgmeno
bmi×hrt
agefirst×nrelbc
agefirst×brstproc
agefirst×lastmamm
agefirst×surgmeno
agefirst×hrt
nrelbc×brstproc
nrelbc×lastmamm
nrelbc×surgmeno
nrelbc×hrt
brstproc×lastmamm
brstproc×surgmeno
brstproc×hrt
lastmamm×surgmeno
lastmamm×hrt
surgmeno×hrt
H measure
Ratio between • “ and • •
Optimal Cut-off point (‰)

70

√
√

71

72
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√
√

√
√

√
√

√
√

√
√

√
√

√
√

√

√

√

√
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√
√
√
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√
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√
√
√

√
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√

√
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√

√

√

√

√

√

√

√
√
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√

√
√
√
√
√
√
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√
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√
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√
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√
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√
√
√
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√
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√
√

√
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√
√

√
√
√
√
√

√

√

√

√

√
√

√
√
√
√

√
√
√
√

√
√
√
√

√

√

√
√

√
√

√

√

√

√

√

√

√

√

√

√
√

√

√
√
√

√
√
√

√
√
√

√
√
√

√
√
√
√
√
√
√
√

√
√
√

√

√
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√
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√
√

√
√

√
√

√
√

√
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√
√

√
√

√
√
√
√

√
√
√
√

√
√
√
√

√
√

√
√

√
√

√
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√
√
√
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√
√
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√
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√
√
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√
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√
√
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√
√
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√
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√
√
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√
√
√

√
√

√
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√
√
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√
√
√

√
√
√

√
√
√
√
√
√
√
√
√
√
0.270 0.270 0.270 0.272 0.311 0.419 0.422 0.425 0.439 0.483 0.550 0.551 0.553 0.546 0.550
838 838 838 830 798 740 666 582 515 483 468 454 424 356 272
4.869 4.869 4.869 4.869 4.598 6.253 6.131 6.102 6.195 6.224 6.721 6.721 6.721 6.833 6.833
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√
√
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√
√
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√
√
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√
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√
√
√

√
√
√
√
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√
√
√

The interaction effects included in each age group are also remarkably different. In particular,
the interaction effect between previous breast procedure and last mammographic result is the
most commonly selected predictor, which appears in 42 out of 45 age groups. The second most
commonly selected interaction effect is the one between age at first birth and last mammogram
(40 age groups), followed by BMI and previous breast procedure (37 age groups). In contrast, the
interaction effect between menopausal status and race is excluded from all age groups.
After the monotone smoothing, the ratio between false negative cost and false positive cost
strictly decreases with age. The cost ratios for young age groups are as high as 2023 (age 40), but
the ratios for older age groups (ages 79-84) fall below 500, implying that the net benefit of
undergoing a mammogram will reduce as a woman ages. In addition, there is also a quasimonotone relationship between age and the optimal cut-off points of predicted probabilities for
accepting a mammogram (Figure 4). Since a higher value of the cut-off point implies a lower
chance of accepting a mammogram, the figure indicates that as women age, they should adopt a
more parsimonious attitude towards annual screening mammography. The curve rises with a
significantly higher rate after age 75, which is consistent with the USPSTF’s recommendation
against routine screening for women 75 years or older.

Optimal Cut-off Points of Mammogram Decision

Optimal cut-off points

‰
8
6
4
2
0

40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84

Age

Figure 4 Optimal cut-off points of probabilities for accepting a mammogram by age
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3.3.4. Sensitivity Analyses
Due to insufficient data in the literature, two sets of parameters may be subject to variability:
disutilities associated with screening () ‘ and ) 1 ) and death rates of untreated invasive cancers

(P UD ). We perform a sensitivity analyses on these parameters to examine the impact of their

variability on the risk model. The sensitivity analyses are conducted on the age groups 40, 60 and
80, which represent the start of screening, mid-point and older age. We adjust these two
parameters (increase or decrease by 10%, 30% or 50% each time) to see whether and how the
cut-off probability of receiving a mammogram in the optimal risk model may change, with the
results summarized in Table 4. “N” suggests that the model stays the same; otherwise, the
differences from the original cut-off probabilities are reported. The results suggest that variation
in the disutilities associated with screening do not impact the risk models and cut-off points in
most cases. However, the risk model is sensitive to the variation in the death rates of untreated
invasive cancers for the 60 and 80 years age groups; even just a 10% increase of Pv UD results
in changed risk models and cut-off points.

Table 4 Sensitivity analyses
Age

Tested Parameter

+50%

+30%

+10%

-10%

-30%

-50%

40

)‘ , )1

+0.052‰

+0.052‰

N

N

-0.024‰

-0.024‰

N

N

N

N

N

60

)‘ , )1

N
+0.798‰

+0.751‰

N

N

-0.034‰

-0.034‰

-0.384‰

-0.384‰

N

+0.079‰

+0.079‰

80

)‘ , )1

-0.384‰
N

N

N

N

N

-0.611‰

-0.494‰

-0.494‰

-0.494‰

N

+0.152‰

+0.152‰

P UD
P UD
P UD

3.3.5. Comparison of Different Screening Policies
For women with an average risk of breast cancer, the ACS recommends that they undergo annual
screening mammography starting at age 45. Women 55 years and older should either switch to
biennial screenings or continue screening annually. We compare the outcome of using the
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decisions generated by our optimal model with that of annual screenings starting at age 45,
which is one of the screening scenarios recommended by the ACS. In addition, in order to
validate the advantage of the tabu search-based risk model, a risk model using all of the breast
cancer risk factors suggested by Barlow et al. (2006) as well as a model using predictors selected
by a simple greedy search are included in the comparison. Likewise, the MCT is used to
determine the optimal cut-off points of generating screening mammogram decisions for the
Barlow model and the model selected by greedy search. We also use AUC as an alternative
criterion in tabu search to demonstrate the superiority of using the H measure over traditional
model selection criteria. Table 5 summarizes the decision policies used in the comparison.

Table 5 Summary of decision models and screening policy for comparison
Search
Model Selection
Mammogram Decision
Decision Policy
Strategy
Criterion
rule
Optimal model
Tabu search
H measure
MCT threshold
Greedy search model Greedy search
H measure
MCT threshold
AUC model
Tabu search
AUC
MCT threshold
Barlow model
N/A
N/A
MCT threshold
Annual screening from
N/A
N/A
Annual mammogram
age 45
We calculate the average loss of life expectancy caused by a single screening decision at each
age when following the decision policies in Table 5. The comparison focuses on the average
impact of a single screening decision at a particular age on a woman’s life expectancy. With the
intention of validating the out-of-sample performance of our proposed model, the loss of life
expectancy for each of the decision models are calculated based on the test set split from the
original dataset. Since every woman in our dataset has in fact undergone a screening
mammogram and been informed of the result, it is straightforward to determine each subject’s
actual loss of life expectancy using the calculated costs of false negative results and false
positive results. Thus, for every age from 45 through 84 years old, we calculate the loss of life
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expectancy for each woman in the age group when the woman adopts each of the five decision
policies. Then we use each woman’s risk characteristics to calculate her possibility of having
breast cancer at her current age, and generate the optimal screening decision for her based on the
optimal threshold. Since whether a woman has cancer is known, we are able to calculate her loss
of life expectancy under different screening decision policies. Then we sum the total losses for
all women in each age group and compute the average loss

=

, for every policy using

²• × • “ + ²n × • •

,

where ²• is the number of cancerous observations which are incorrectly identified as non-

cancerous by the given decision model; ²n is the number of non-cancerous observations which

are falsely identified as cancerous by the given decision model; and

is the total number of

observations in age group t.
The age-specific average losses of the five decision policies are plotted in Figure 5. Our
optimal decision model consistently outperforms the annual screening and the remaining four
decision models. When following the optimal decisions, the average loss of life expectancy
caused by a single decision ranges between 0.001062 and 0.001663 years. The annual screening
policy results in a significantly higher range of loss (between 0.001699 and 0.001738 years) as
compared with our optimal decisions. Adopting the ACS’s biennial mammography screening
after age 54 incurs higher loss of life expectancy (results not shown on Figure 5). In addition, the
average loss of switching to biennial screening mammography after age 54 ranges from 0.01678
to 0.00521 years, which is three to nine times higher than the average loss when continuing
annual mammography at the corresponding ages. The decision model based on the Barlow model
shows slightly better outcomes compared to the annual screening policy. The performance of the
model selected by a simple greedy search lies between the Barlow model and the optimal model.
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The decision model selected by the AUC has the worst out-of-sample performance, which may

Average loss of life expectancy (yrs)

be due to the ROC curve assigning the same weights to false positive and false negative errors.
0.002100
0.001900
0.001700
0.001500
Optimal Model
Greedy Search Model
Barlow Model
Annual screening
AUC Model

0.001300
0.001100
0.000900
45

50

55

60

Age

65

70

75

80

Figure 5 Comparing the optimal decisions with the annual screening policy and other models
Figure 6 presents the optimal cut-off probabilities associated with the four decision models
starting at age 45. The annual screening policy does not make screening recommendations based
on risk probabilities, and thus is not compared. The cut-off points from the greedy search model
are closest to those of the optimal model. The cut-off points of the AUC model are significantly
higher than the other three models, while the Barlow model has the lowest cut-off points among
the four models. Since the Barlow model uses the same predictors for all age groups, it has a

Optimal Cut-off Probabilities
(‰)

smoother curve than the other three models.
Optimal Model
AUC Model
Greedy Search Model
Barlow Model

10
8
6
4
2
0
45

50

55

60

65

70

75

80

Age

Figure 6 Comparing the optimal cut-off probabilities associated with the four decision models
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We further compare the five screening policies in terms of the total number of screening
mammograms recommended in the population using the test set. As shown in Table 6, our
optimal model recommends the second lowest number of screening mammograms (331,504),
which is only 86% of the total number of mammograms recommended in the annual screening
policy (384,900). Therefore, using the optimal screening policy developed in this study not only
decreases the loss of life expectancy of the general population, but also potentially reduces the
amount of medical expenses on breast cancer screenings.

Table 6 Total number of mammograms under different policies
Total Number of
Ratio to the Annual
Decision Policy
Mammograms
Screening Policy
AUC model
310501
81%
Optimal model
331504
86%
Greedy search model
358603
93%
Barlow model
374564
97%
Annual screening from age 45
384900
100%
It is noteworthy that the comparison is based on the general population, which includes both
low risk and high risk women, so that the average differences of loss between the optimal
policies and other policies are low in terms of magnitude (less than one day). However, a lifetime
cumulative comparison would make a more dramatic difference. In addition, if we were to apply
the same comparison to a group of low risk women, instead of the general population or high risk
women, we expect the differences to be sharper, as our optimal decision model propels low risk
women to undergo fewer mammograms.

3.4 Discussion and Future Work
This paper presents a personalized decision-making model that aims to minimize the negative
effects of current breast cancer screening practice. In Figure 7, we illustrate the process of using
our personalized model to make screening mammogram decisions in practice. Whether a woman
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should receive a screening mammogram is determined based on her risk level in the current year,
our “on-line” screening policy is adaptive to a woman’s health status. While most previous
studies strive to improve the breast cancer screening guidelines by offering lifetime
mammography screening schedules, our model proposes utilizing a dynamic decision aid to
determine if breast cancer screening should be conducted in the current year. The personalized
model does not attempt to answer when to start or end routine mammography screening and how
often women should be screened, but instead uses a woman’s personal risk of breast cancer and
the net benefit of receiving a screening mammogram as two variable constraints to dynamically
adjust the screening decision. As a uniform and static breast cancer screening policy is by no
means perfectly applicable to different women or even the same woman at different time points,
this research may inform the long-term controversies on breast cancer screening policies.
Furthermore, the two-stage decision-making framework proposed in this study could also be
applied to other disease prevention and treatment areas, such as prostate cancer screening, as
long as there exists a binary decision-making process and the costs of two types of wrong
decisions can be well quantified.

A woman needs
to decide on
mammography
screening for
the current
year.

Based on her
age, we choose
the appropriate
risk estimation
model for her.

We use the
woman’s risk
characteristics
to estimate her
risk of breast
cancer.

Yes
Is the risk
higher than
the optimal
cut-off?

The woman
undergoes a
mammogram
immediately.

No
Mammogram is
not
recommended.
The woman
should wait
until next
year.

Figure 7 Flow chart of mammography decision-making process
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There are methodological contributions in this study. Different from previous personalized
optimization models that do not purposely select variables but adopt all available static risk
factors, the determinants of the proposed risk estimation model are selected based on a particular
focus, i.e., making an optimal decision that minimizes the expected cost of false prediction. This
study combined the H measure, a novel prediction-cost-oriented criterion of classification and
prediction problems, with an efficient heuristic search algorithm model selection to overcome the
high dimensionality of explanatory variables and the large number of observations. We expect
this combination can provide new insights into the improvement of efficiency and effectiveness
when dealing with large scale problems, especially for medical decision making. Meanwhile, we
incorporate interaction effects between different risk factors to the risk estimation model of
breast cancer. Many prior studies revealed that different risk factors do not affect women’s breast
cancer risk independently (Mayberry and Stoddard-Wright 1992, Cleary and Maihle 1997,
Clavel-Chapelon and Gerber 2002). However, earlier risk estimation studies fail to directly
formulate these possible interaction effects in their model (Gail and Rimer 1998, Gail et al. 1989,
Barlow et al. 2006). While stratifying risk models by age is commonly adopted, interaction
effects between other risk factors have received little attention in previous screening
mammography optimization studies. Our results show that interaction effects between risk
factors play a critical role in the decision process.
A major limitation of this study is the estimation of the misclassification cost of a false
negative result. Life expectancy calculation (

ins

and

inv ) is based on the assumption

that a woman will strictly undergo annual screening mammograms in the future. In fact, whether
the woman will receive mammograms in the subsequent years depends on her future risk factors.
However, since the misclassification cost of a false negative result is considered as the difference
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between the life expectancies of skipping a necessary screening mammogram and receiving a
necessary screening mammogram, the subtraction greatly offsets the possible bias caused by the
assumption. Another major limitation is that the model incorporates only the most recent
mammogram result as a risk factor, rather than the full history of previous mammography
screenings. Different numbers of prior negative and positive mammography results may indicate
different levels of risk. Moreover, the interval between the last mammogram and the current time
point may also make a difference in terms of cancer risk. Due to the fact that the BCSC dataset
only contains one observation per woman, we are only able to consider the most recent screening
mammogram regardless of the number or interval, which is a common practice in prior studies
(Barlow et al. 2006, McCann et al. 2002). Lastly, some parameters in our model are based on the
general population rather than being woman-specific. For instance, different women may have
different cancer progression rates, but the progression rates used in this study are age-specific,
which means all women in the same age group share the same cut-off probability regardless of
their risk characteristics. To the best of our knowledge, there is no information on these patientspecific parameters reported in the literature. The model proposed in this study will be able to
personalize both risk models and optimal cut-off points when such information becomes
available in the future. Compared with Markovian models, our proposed method has a
disadvantage in representing the abovementioned dynamics of the breast cancer screening
problem. Our model requires a significant amount of data to properly incorporate these dynamics
and such large data is unavailable in most cases. Although the proposed method is capable of
processing dynamic risk factors, it primarily focuses on the current decision epoch and does not
sufficiently model the women’s screening decisions in the future, which may potentially impact
the outcome (i.e., total life expectancy) of the current screening decision.
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As a future research direction, a different model could be formulated to determine optimal
decisions for women who have a personal history of breast cancer and who are undergoing
surveillance mammography. The risk of cancer recurrence is not only affected by the identified
breast cancer risk factors but also by type of treatment, number of years since treatment, and
initial tumor characteristics (Buist et al. 2010). Using the methods developed in this study with
data on women with a personal history of breast cancer may allow for the creation of another
model that will contribute to our ability to generate personalized recommendations for
prevention and control of breast cancer.
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4 Personalized Modeling for Assessing Human Papillomavirus (HPV) Vaccination Policies
for Women

Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United
States. HPV can cause genital warts and multiple types of cancers on females, including cervical,
anal, vaginal, vulvar, and oropharyngeal cancers. In order to prevent future HPV-related
diseases, currently, all boys and girls ages 11 or 12 years are recommended to receive the threedose HPV vaccine. Catch-up vaccines are recommended for males and females through ages 21
and 26, respectively, if they have not been vaccinated previously. In this research, we
hypothesize that the cut off age of catch-up vaccine should be determined based on every single
woman’s risk characteristics, rather than a one-size-fits-all age 26. We model the impact of HPV
vaccination at different ages on every individual and track her course of life to estimate the
clinical outcomes that resulted from receiving vaccines. With the purpose of providing patientspecific HPV vaccination strategies, especially personalized catch-up vaccination policies, we
develop a discrete-event simulation model to evaluate multiple clinical consequences after a
woman is vaccinated based on a number of personal attributes. As our simulation model works at
the individual level, we build an HPV risk estimation model reflecting every woman’s HPV risk,
which dynamically changes over time, to support the lifetime simulation model. We estimate the
following patient-specific clinical consequences: life time risk of developing HPV-related
cancers, life expectancy, life years saved by vaccines. Our study shows that catch-up vaccines
still benefit all women after age 26 from the perspective of clinical outcomes. Especially, women
facing high risk of HPV infection is expected to gain more health benefits compared with women
with low HPV risk. The study reveals that the optimal HPV vaccination catch-up policy should
be personalized for different women.
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4.1 Introduction
Human papillomavirus (HPV) is the most common sexually transmitted disease in the United
States. According to Satterwhite et al.’s estimation (2013), 14,100,000 people are newly infected
with HPV each year. Among over 150 identified HPV subtypes, more than 40 HPV types can be
transmitted via sexual contacts (Bernard et al. 2010). Although most HPV infections are
asymptomatic and often regress on their own spontaneously, some HPV subtypes can cause
genital warts and multiple types of cancers for females, including cervical, anal, vaginal, vulvar,
and oropharyngeal cancers. In particular, HPV types 16 and 18, result in 70% of cervical
cancers, which is the second largest cause of cancer deaths among women worldwide. (Arbyn et
al.2011, Lowy and Schiller 2012).
While there is no effective treatment for HPV, HPV infections can be prevented through
vaccination. Currently, three vaccines have been approved by the Food and Drug Administration
(FDA), including Gardasil (bivalent vaccine), Cervarix (quadrivalent vaccine) and Gardasil 9 (9valent vaccine). While bivalent HPV vaccine protects against HPV 16 and 18, quadrivalent
vaccine protects against HPV 6 and 11 in addition to HPV 16 and 18. 9-valent vaccine, which
was newly approved by FDA, provides protection against HPV types of 6, 11, 16, 18, 31, 33, 45,
52, and 58. Although the HPV subtypes covered by the three vaccines vary, all of them provide
strong protection against HPV 16 and 18, which account for most HPV-related cancers. The
American Cancer Society (ACS) recommends that girls and boys should receive HPV
vaccination at age 11 to 12 (Saslow et al. 2016). For those who have not previously been
vaccinated, catch-up HPV vaccination is also recommended for females through age 26 and for
males through age 21.
Since the introduction and implementation of HPV vaccination, significant reductions in
vaccine type infections among women have been reported. Markowitz et al. (2013) found a 56%
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decrease in the prevalence of vaccine-type HPV among females aged 14 to 19 years in the 4
years after vaccine introduction. A clinic-based study reported substantial decrease in the
prevalence of vaccine-type HPV in both vaccinated and unvaccinated women from a community
4 years after the quadrivalent HPV vaccine was introduced (Kahn et al. 2012). Previous studies
also suggested substantial reduction in HPV-related diseases. Ali et al. (2013) reported that there
was a 60% reduction in new cases of genital warts. Clinical trials showed that HPV vaccines
have very high efficacy for prevention of vaccine-type pre-cancers. Specifically, the efficacy of
bivalent and quadrivalent against cervical pre-cancer is higher than 93% (Dunne et al. 2014).
Previous studies evaluated HPV vaccination program at the population level. Most of these
studies assessed the cost-effectiveness and clinical outcomes of HPV vaccination program based
on simulation models. Sanders and Taira (2003) developed a Markov model to evaluate the costeffectiveness of vaccinating adolescent girls with high-risk of HPV infections. They assumed a
75% probability of immunity against high-risk HPV infection and found that such a vaccine
would result in a gain of 4 quality-adjusted life days at a cost of $246. If all 12-year-old girls in
the United States were vaccinated, over 1,300 deaths from cervical cancer would be prevented.
Elbasha et al. (2007) assessed the clinical outcomes and cost-effectiveness of quadrivalent
vaccines and found that vaccinating girls before age 12 would reduce the incidences of genital
warts and cervical cancers by 83% and 78%, respectively. Chesson et al. (2008, 2011) estimated
the decrease in the health and economic burden of HPV-related diseases in males and females as
a result of HPV vaccination. Their models incorporated cervical, vaginal, vulvar, anal,
oropharyngeal, and penile cancers as well as genital warts. Guzzetta et al. (2014) estimated the
impact of HPV vaccination on Italian women. Their study also found that catch-up vaccines of
25-year-old women can avert 9.6% of all cervical cancer cases expected in the scenario without

100

catch-up. Velde et al. (2011) investigated why different HPV vaccination evaluation studies
usually produced very inconsistent results. They concluded that differences in the elements of
model design, such as natural immunity, partnership duration, HPV types, and waning of vaccine
protection, result in significant differences in the estimated effectiveness of HPV vaccines.
However, to the best of our knowledge, there is no study evaluating HPV vaccination at the
individual level. As Velde et al. (2011) suggested, differences in some model parameters may
result in very different outcomes. It is reasonable to expect that people with different levels of
HPV risk have very different clinical outcomes after receiving vaccines. Previous studies
identified a number of risk factors that determine the level of HPV risk on different women,
including demographic attributes, personal life style and sexual behavior (Winer et al. 2003,
Dempsey 2008, Shi et al. 2014). The HPV risk varies dramatically on different individuals. Thus,
a personalized evaluation model incorporating individual HPV risk will precisely reveal the
different impacts of HPV vaccination on different people.
In addition, although the current HPV vaccination guideline proposed by the ACS does not
recommend vaccines for women older than 26, recent studies showed that women over the age of
26 still bear significant HPV risk (Velentzis et al. 2014). In some other countries, HPV
vaccination recommendations go beyond age 26. Particularly, in Australia, HPV vaccines are
registered for use in females up to 45 years old (Mazza et al. 2014). Some studies showed that
HPV vaccines are still beneficial to older women (Muñoz et al. 2009, Schwarz et al. 2009,
Westra et al. 2011). Those conclusions were drawn mainly from the efficacy perspective rather
than from cost-effectiveness considerations.
In this study, we address the abovementioned problems with two objectives: (1) providing a
personalized evaluation model of HPV vaccination, and (2) examining the clinical outcomes of
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HPV vaccination for women older than 26. We also seek to synthesize these two problems and
determine the cut-off age of HPV catch-up vaccine based on every single woman’s risk
characteristics. Our study models the impact of HPV vaccination at different ages on every
individual, and tracks her course of life to estimate the clinical outcomes that has resulted from
receiving vaccines. With the purpose of providing patient-specific HPV vaccination strategies,
especially personalized catch-up vaccination policies, we develop a discrete-event simulation
model to evaluate multiple clinical consequences after a woman receives vaccines based on a
number of personal attributes. As our simulation model works at the individual level, we build an
HPV risk estimation model incorporating every woman’s HPV risk, which dynamically changes
over time, to support the lifetime simulation model. We estimate the following patient-specific
clinical consequences: life time risk of developing HPV-related cancers, life expectancy, life
years saved by vaccines.
The contribution of our study is two-fold. Firstly, this is the only patient-specific simulation
model for the evaluation of HPV vaccination, which provides more practical and accurate
decision support for both individual woman and medical decision makers. The model proposes a
new framework which is able to reflect the dynamic HPV risk of an individual during the
simulated life course. Secondly, our study considers vaccination after age 26, which exceeds the
recommended age of catch-up vaccines in the U.S. The results of the study would be
instrumental for medical decision makers to rationally determine the catch-up vaccination and
potentially amplify the public health benefits of HPV vaccines.
The remainder of the chapter proceeds as follows. Section 4.2 introduces the basic
framework of the simulation model and the adjunct HPV risk model. Section 4.3 presents the
numerical experiment performed. We introduce the model input, data processing and experiment
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results under different scenarios in this section. Section 4.4 provides a discussion on the
proposed model and concludes the significance of the study.

4.2 Methodologies
The HPV vaccination evaluation model consists of two sub-models. The main body of the model
is a discrete event simulation model that keeps track of every individual woman’s course of life,
which involves multiple deterministic events and probabilistic events. An HPV risk model
dynamically estimates the patient-specific HPV risk of every simulated woman’s life course so
as to update the likelihoods of probabilistic events while a simulation is running.

4.2.1. Estimation of Clinical Consequences Using Discrete Event Simulation
We use a discrete event simulation to model individual women’s course of life in different
vaccination scenarios (i.e. varying age at vaccination). The model simulates every woman’s life
course with the given risk characteristic repeatedly over a planning horizon from the starting age
to age 100. The system clock is incremented by a fixed amount of time at each step of the
simulation. In this study, we define the increment of time by 1 year. We use to represent the
current time epoch (i.e. a woman’s age). We use five main states to represent a woman’s health
status.

•

Susceptible (S): the woman has no immunity against HPV and therefore is susceptible to
HPV

•

Immune (I): the woman has been vaccinated and therefore is immune to HPV

•

HPV infection (H): the woman without immunity is infected with HPV.

•

Cancer (C): the woman has developed an HPV-related cancer.

•

Death (D): the woman dies from HPA-related cancers or other causes.
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A woman’s state at time is denoted by

, where

∈ S, I, H, C, D . During the course of a

woman’s simulated life, her health status will switch between the five states until she enters
death or reaches age 100. There are both deterministic events and probabilistic events that may
change a woman’s state. Table 1 summarizes the main deterministic events and probabilistic
events in a woman’s simulated life course. Figure 1 shows the five states and the specific events
resulting in the transitions between these states. In particular, we assume all women complete 3dose HPV and acquire full immunity against HPV. As the long-term clinical trials that follow up
the HPV vaccines’ protection duration are still ongoing and have reported almost persistent
efficacy during the whole follow-up period (Romanowski et al. 2016), we also assume that
vaccines provide women with lifetime immunity against HPV infection, which is a common
practice in previous studies (Elbasha et al. 2007). Thus, once a woman gets vaccinated, she will
never enter “HPV infection” or “Susceptible” states. At each step of the simulation, the system
determines the occurrences of the events based on the woman’s current state and the
corresponding likelihoods of probabilistic events. The woman stays in one of the states until an
event occurs and changes her state.

Table 1 Main events in the simulation model
Deterministic events
Probabilistic events
▪ The woman will get vaccinated ▪ The woman may or may not be infected with
at a specific age.
HPV.
▪ She will die at age 100 if not ▪ After the woman is infected with HPV, the
dying at an earlier age.
HPV may regress spontaneously.
▪ After the woman is infected with HPV, the
HPV may progress to an HPV-related cancer.
▪ If the woman develops an HPV-related
cancer, the cancer may result in death or be
successfully treated.
▪ The woman may die at any age.
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The woman gets vaccinated

Susceptible (S)

The woman
is
infected
with HPV

Immune (I)

HPV regresses
spontaneously

Cancer
regresses
and HPV
clears

Death (D)

HPV progresses to a cancer

HPV infection
(H)

Cancer (C)
Cancer regresses and HPV
persists

Figure 1 The main structure of the simulation model
Let :

&

|

denote the transition probability from state

to state

&

for a woman at

age t. Table 2 summarizes how the transition probabilities are determined.

Table 2 States transitions in the simulation model
Probability
Transition
: H|S

: S|H

: D|H
: C|H
: D|C
: D|I

: D|S
: I|S

: H|C
: I|C

Value
Patient-specific annual HPV
The woman is infected with HPV.
incidence rate
HPV regresses spontaneously.
One-year regression rate of HPV
The infected woman dies from reasons
One-year death rate (excluding
other than HPV-related cancers.
HPV-related cancers)
Cancer-specific one-year
HPV progresses to an HPV-related cancer.
progression rate of HPV
The woman dies from any reasons,
Cancer-specific one-year death
including HPV-related cancer.
rate (including other reasons)
The uninfected woman dies from reasons One-year death rate (excluding
other than HPV-related cancers.
HPV-related cancers)
The uninfected woman dies from reasons One-year death rate (excluding
other than HPV-related cancers.
HPV-related cancers)
100% at a specified age
The woman gets vaccinated.
0% at other ages
The HPV-related cancer regresses. HPV
HPV persistent rate after cancer
persists.
treatment or cancer regression
The HPV-related cancer regresses. HPV
1 - HPV persistent rate
clears.
(excluding death in one year)
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Different from other states, “cancer” is a complex state that consists of several sub-states
representing the development, diagnosis and treatment of HPV-related cancers. Figure 2
illustrates the subsequent process after a woman’s HPV develops to HPV-related cancers. We
use multiple sub-states to differentiate detected and undetected HPV-related cancers as well as
different stages of the cancers, as they have different death rates. The simulation clock is still
incremented by one year at each step after a woman enters the sub-states of the “cancer” state.
When a woman completes the transitions from “HPV infection” state to “cancer” state, she will
immediately be assigned to “pre-cancer/ in situ cancer” state. Then the woman’s pre-cancer or in
situ cancer may progress to a invasive cancer or be diagnosed. The state transitions in the substructure are similar to the transitions in the main structure of the simulation model.

Survivor

Detected precancer/ in situ
cancer

Pre-cancer/ in
situ cancer

Detected Local
cancer

Undetected local
cancer

Detected
regional cancer

Undetected
regional cancer

Detected distant
cancer

Undetected
distant cancer

Death

Figure 2 The sub-structure of the “cancer” state
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Every year, a simulated woman’s health status may stay at the same state or change to
another state with a certain possibility. The woman’s status switches between the different states
until she enters an absorbing state (i.e. “survivor” or “death”) or leave the sub-structure (i.e., two
outgoing arrows from the “pre-cancer/ in situ cancer” states).
We take cervical cancer as an example to explain the detailed simulation process after a
woman’s HPV progresses to HPV-related cancer. Every year, an HPV infection may naturally
progress to HPV-related cancers with a certain probability. The first status after the progression
is the pre-cancer or in situ cancer stage. For cervical cancer, this status includes three states:
cervical intraepithelial neoplasia (CIN) 1, CIN 2 and CIN 3, which are cervical cancer’s nonmalignant pre-cancer stages with the propensities of regression and progression (Schiffman et al.
1993). These pre-cancer stages may be detected by routine cervical cancer screening (i.e., Pap
test) with a certain probability every year. Once detected, the CINs will be treated. Then the
simulated woman will re-enter “HPV infection” state or “Immune” state in Figure 1, depending
upon whether the HPV infection persists or not. During the year, the woman may also die from
another causes other than cervical cancer. If the CINs are not detected, the woman’s status may
stay the same, regress to “HPV infection”, regress to “Immune”, or progress to a real cancer, i.e.
local cervical cancer. When the woman enters “undetected local cancer” state, similarly, the local
cancer has potentials of evolving to a regional cervical cancer and being detected. Since the
woman has cervical cancer, there is a certain possibility for her to develop cancer-related
symptoms, which finally results in diagnosis and treatment of the cancer. The combination of the
symptom development rate and cervical cancer screening rate is the transition probability from
undetected local cancer to detected local or regional cancer. If the cancer is detected, the woman
will enter the “detected local cancer” state and end up with “survivor”. The “survivor” state
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makes the simulated woman quit the simulation and be assigned with a lump-sum life
expectancy based on her specific cancer stage. A similar process is true for regional cancer and
distant cancer.
In addition to cervical cancer, HPV has been identified as an important cause of four other
cancers of women, including anal cancer, vaginal cancer, vulvar cancer and oropharyngeal
cancer (Chaturvedi 2010). The simulation model takes into account the five HPV-related
cancers. We assume that a woman will never develop multiple HPV-related cancers
simultaneously, as the incidence of synchronous primary cancers of the female genital tract is
very rare (Tong et al. 2008). An HPV infection may progress to one of the five cancers with a
certain probability every year. Once a woman develops an HPV-related cancer, she is
temporarily free from the other cancers.
The goal of the simulation is to estimate patient-specific clinical consequences in different
vaccination scenarios (i.e. varying age at vaccination) and with given individual HPV risk
characteristics. A woman’s life course is simulated for multiple times to derive the average
values of life time risk of developing HPV-related cancers and life expectancy. By changing the
age at vaccination and performing the simulation on women with different HPV risk, we expect
to receive dramatically different outcomes of these metrics.

4.2.2. HPV Risk Model
In the simulation model, individual HPV risk is embodied in the transition possibility : H|S ,
which is from “Susceptible” to “HPV infection”. Different women’s possibilities of being
infected with HPV at every age are estimated based on their personal risk characteristic. Previous
studies have identified several behavioral and demographic risk factors of HPV (Moscicki et al.
1990, Winer et al. 2003, Dempsey 2008, Shi et al. 2014, Reiter and McRee 2016). We use a
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number of identified HPV risk factors to build a penalized regression model to estimate the
personal HPV risk for every individual, including demographic attributes, personal life style and
sexual behaviors.

Table 3 Candidate HPV risk factors
Demographic attributes
Age
Race
Marital status
Ratio of family income to
poverty
Age at first menarche
Parity

Personal life style
Recent alcohol use
Recent tobacco use

Sexual behaviors
Age at first sex
Lifetime number of sex partners
Number of recent sex partners
Sex orientation

Table 3 summarizes the twelve candidate variables that are used to build the HPV risk
model. We use these risk factors to determine every individual’s HPV risk at different ages. The
risk factors are employed as the predictors of the logistic regression model to estimate the HPV
risk. Since HPV 16 and 18 are responsible for most HPV-related cancers and preventable by the
three approved vaccines, we only take these two HPV subtypes into account and treat the
incidence of HPV 16 and 18 as a single binary variable. Thus, the response variable is whether a
woman has HPV 16 or 18 at her current age.
However, it might not be necessary to include all available predictors in the regression
analysis. Firstly, we need a parsimonious model – some risk factors are dynamic and therefore
intractable to be tracked over time, such as number of sex partners. The change of a variable in a
woman’s life time needs to be fully modeled. Therefore, a simple model with as few predictors
as possible would greatly reduce the difficulty of data preparation. Secondly, multicolinearity
may exist in the model, as many variables are inherently correlated. For instance, a woman’s
marital status is naturally correlated with the number of her recent sex partners. Thirdly,
incorporating too many variables may result in overfitting, which leads to a poor out-of-sample
predictive power. Thus, we choose lasso regression to perform variable selection for the logistic
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regression as it penalizes multicollinearity by removing correlated variables while pursuing a
good predictive performance. The optimal tuning penalty parameter (lambda) is determined by
a10-fold cross-validation. Optimality is evaluated based on the area under curve (AUC) since the
data are highly unbalanced (i.e., observations with response variables equal to 0 make up the vast
majority of the data).
In order to be easily tracked over time, all numerical candidate variables are converted to
categorical variables, which means regular lasso regression may have undesirable results. Firstly,
lasso regression makes the matrix of predictors sparse—every categorical variable is broken
down to multiple dummy variables, resulting in very high column dimension. Secondly, lasso
regression often partially selects dummy variables—it is not reasonable to select only a portion of
dummy variables from one categorical predictor. Especially, lasso regression may not be able to
reduce the difficulty of data collection. It may only remove part of the dummy variables derived
from a predictor, which means the predictor still needs to be considered and fully prepared in the
simulation model.
Therefore, group lasso (Yuan and Lin 2006, Meier et al. 2008) is an appropriate choice of
penalization method for multicollinearity in this case. The group lasso does variable selection on
predefined groups of variables in regression models, which allow us to group all dummy
variables from a categorical variable and manipulate them at the same time. In a typical logistic
regression set-up, assume that we have a binary response variable ´„ ∈ 0,1 and G independent

p
variables }„ = }„,p , … , }„,µ

p

with }„,¶ ∈ ℝ¸¹º , where » = 1, … , ¼. And df¶ is the degree of

freedom. In the context of this study, the categorical variable with three levels has a df¶ = 2,

while a numerical variable has df¶ = 1. The conditional probability %½ }„ = %½ | = 1| }„ is
modeled by
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%½ }„
¿ = À½ }„ ,
1 − %½ }„

(1)

p
À½ }„ = •j + ∑µ¶Á }„,µ
•¶ ,

with

where •j is the intercept; •¶ is the coefficient vector of the gth independent variable with a

degree freedom of df¶ . So the estimator •Â– is calculated by minimizing the convex function
–

• = −Ã • + — ∑µ¶Á

where Ã • = ∑„Á ´„ À½ }„ − log 1 + eÅÆ

df¶ Ä•¶ Ä ,
4

°Ç

(2)

, which is the log-likelihood function of • (Meier

et al. 2008). — is a non-negative tuning parameter that controls the strength of penalization.

Idf¶ J = Èdf¶ is used to rescale the penalty with respect to the dimensionality of the coefficient

vector •¶ and ensure that the penalty is of the order of df¶ . For a logistic regression with

categorical variables, all dummy variables from the same categorical variable are grouped, so
they are either entirely kept or discarded during the variable selection process.
We adopt the logistic regression penalized by the group lasso method to build the HPV risk
model and use the HPV risk as the input for the transition possibility : H|S , which represents
the change from the “susceptible” state to the “HPV infection” state. Then the simulation is
personalized for different women and generates patient-specific clinical outcomes.

4.3 Numerical Experiments
4.3.1. Parameter Estimation For Simulation Model
Table 4 summarizes the data sources that are used to estimate the transition probabilities between
the main states in the simulation model. It is worth noting that our HPV risk model actually
outputs the prevalence of HPV associated with people having specific risk characteristics. For
initial state distribution of every individual woman at the beginning of the simulation, we use the
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HPV risk model to estimate the prevalence of HPV and assign the woman to either “Susceptible”
or “HPV infection” states according to the calculated prevalence. The epidemiologic equation

Prevalence = Incidence × Duration (Aschengrau and Seage 2013) is used to calculate

Pv H|S , which is the incidence associated with a specific risk characteristic. The 1.2 years
duration of oncogenic HPV 16/18 infection is adopted (Elbasha et al. 2007).

Table 4 Sources of data input for transition probabilities
Transition Probability
Source for Parameter Estimation
refer to the HPV risk model in Section 4.3.2
: H|S
Sanders and Taira 2003
: S|H
Arias et al. 2016
: D|H
Elbasha et al. 2007, Chesson et al. 2008
: C|H
Adriano et al. 2003, Elbasha et al. 2007, Arias et al. 2016
: D|C
Arias et al. 2016
: D|I
Arias et al. 2016
: D|S
100% at specified vaccination age, and 0% at other ages
: I|S
Elbasha et al. 2007
: H|C
Elbasha et al. 2007
: I|C
This study considers five HPV-related cancers, including cervical cancer, anal cancer,
vaginal cancer, vulvar cancer and oropharyngeal cancer. Therefore, there should be five different
sub-structures of “cancer” state, each of which represent one of the five cancers. For the annual
progression rates, annual regression rates, annual symptom development probabilities, annual
screening rate and stage-specific annual death rates of cervical cancer, we use the data reported
by Sanders and Taira (2003) as well as Elbasha et al. (2007). For the stage-specific lump-sum
life expectancy of the absorbing state “survivor”, we use the DEALE method based on the 5-year
survival of invasive cervical cancer (Beck et al. 1986, Howlader et al. 2013).
However, unlike cervical cancer, there are relatively limited epidemiological data on the
nature history, diagnosis and prognosis of anal cancer, vaginal cancer, vulvar cancer and
oropharyngeal cancer. Due to the low incidences rates of these four cancers, most prior studies
on HPV vaccination evaluation only took cervical cancer into consideration and focused on HPV
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vaccination’s health outcomes from the perspective of cervical cancer prevention (Sanders and
Taira 2003, Elbasha et al. 2007, Ley-Chavez 2012, Guzzetta et al. 2014). Therefore, our study
simplifies the four HPV-related cancers’ impacts of the four HPV-related cancers on women’s
life expectancy by introducing the loss of life years associated with different cancers reported by
Chesson et al. (2008), rather than use the sub-structures of “cancer” state to simulate the
outcomes of these cancers. Once a woman develops one of the four cancers, her life expectancy
is deducted by a certain amount of life years (Chesson et al. 2008), which are not only cancerspecific but also age-specific.

4.3.2. Parameter Estimation for HPV Risk Model
We use the National Health and Nutrition Examination Survey (NHANES) 2011-2012 data to
build the individual HPV risk model. 13,431 people from 30 different study locations across the
US participated in the survey. The publicly available datasets include data for people aged 18-59
years. The NHANES data report a large number of personal information of participants,
including demographic, socioeconomic, dietary, and health-related information as well as
medical laboratory exam results, which cover all the variables summarized in Table 3.
Especially, the NHANES 2011-2012 include exam results of multiple HPV subtypes. It provides
us an access to evaluate the risk of HPV infection in different groups.
However, one critical issue of NHANES data that needs to be addressed is its large number
of missing data. Although 13,431 people were included in the survey, only 1,767 observations
include HPV 16/18 data for participants. It is noteworthy that, among the 1,767 observations,
only 247 subjects have complete data in all the twelve candidate variables. If we use the simple
listwise deletion to deal with missing values (i.e. as long as there is at least one variable with
missing value, the whole observation is removed), the deletion procedure would discard around
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86% of the observations, which results in a considerable loss of data and potential bias.
Following the previous studies that dealt with a large number of missing values in training data
(Barlow et al. 2006, Shi et al. 2014), we treat the missing values in category variables as a single
level “unknown” and only remove the observations with unknown or missing values in
numerical variables (e.g. age).
The infection of HPV 16/18 (i.e. positive exam result) is modeled as the response variable
in the regression analysis. We also exclude all women who have been vaccinated before they
took the surveys. We conduct the group lasso variable selection on the twelve candidate
variables and find the best combination of HPV risk factors.
Since the study simulates every woman’s lifetime, our model takes into account the change
of every individual’s risk characteristic. Among the twelve candidate risk factors, eight of them
are dynamic and change over time, including age, marital status, ratio of family income to
poverty, recent alcohol use, recent drug use, parity, lifetime number of sex partners, and number
of recent sex partners. Age is simply increased by 1 with every increment of the system clock.
For the remaining seven dynamic variables, longitudinal data are needed to track their changes
over a long period of time. Moreover, the relationships between HPV risk and some variables are
not necessarily linear. In order to simplify the tracking process, we convert all numerical
dynamic variables to categorical variables. Specifically, “age” is categorized by 5-year age
groups, starting with group “20-24”. We model “ratio of family income to poverty” as a binary
variable with 1 indicating that the ratio is lower than or equal to 1, and 0 indicating that the ratio
is higher than 1. “Parity” is also converted to a binary variable with 1 indicating that the woman
has had a live birth, and 0 indicating that the woman has no live birth. As heavy drinking is
defined as 8 or more drinks a week for women (U.S. Department of Health and Human Services
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2015), we convert recent alcohol use to a binary variable with 1 indicating the woman drink
more than one alcoholic beverages on average every day in the past 12 months, and 0 indicating
not more than one drink every day. For “lifetime number of sex partners”, we use five levels,
“=0”, “1”,”2-4”,”5-9”,”>=10”, and “unknown”, to categorize the variable. “Number of recent
sex partner” is categorized by “0”, “1”, “>=2” and “unknown”. In addition, although “age at first
menarche” and “age at first sex” are not dynamics variables, in order to incorporate missing
values, we also categorize them using five levels, “<=12”, “13-15”, “16-19”,”>=20” and
“unknown”.

Table 5 Model selection result
Candidate variable
Age
Race
Marital status
Ratio of family income to poverty
Age at first menarche
Parity
Recent alcohol use
Recent tobacco use
Age at first sex
Lifetime number of sex partners
Number of recent sex partners
Sex orientation

Original data type
Numerical
Categorical
Categorical
Numerical
Numerical
Numerical
Numerical
Numerical
Numerical
Numerical
Numerical
Categorical

Property
Dynamic
Static
Dynamic
Dynamic
Static
Dynamic
Dynamic
Dynamic
Static
Dynamic
Dynamic
Static

Selected
Yes
Yes
Yes
No
No
Yes
No
Yes
Yes
No
Yes
No

The entire analysis is performed in R 3.32. Using the group lasso logistic regression, seven
variables are selected (Table 5). Among the seven selected variables, age, race, age at first
menarche and age at first sex are either static or uniformly increased. In contrast, the values of
marital status, recent tobacco use, parity and number of recent sex partners are fluctuating and
need to be modeled throughout every woman’s whole life. During the simulation, if one of these
variables has any changes, the HPV risk is also updated accordingly. We use multiple data
sources to model these dynamic variables as follows.
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Marital status
We model women’s changes of marital status based on the method proposed by LeyChavez (2012). Five statuses are considered in the model, including first marriage, first divorce,
second marriage, second divorce and never-married. The duration of each status is modeled by a
discrete distribution depending on age. The basic process of modeling marital status proceeds as
follows. The simulation randomly assigns an age of first marriage to women based on the
probability distribution estimated from the Survey of Income and Program Participation (U.S.
Census Bureau 2015). The marriage will last for a certain amount of time or a lifetime, based on
the probability distribution of 1st marriage duration estimated using the National Survey of
Family Growth (Centers for Disease Control and Prevention data 2002) and the Survey of
Income and Program Participation (U.S. Census Bureau (2015). Once a woman divorces, her
length of divorce status is determined by a probability distribution reported by the Survey of
Income and Program Participation. A divorced woman may get married for the second time. In
addition, the duration of a woman’s second marriage is determined by a probability distribution,
using the data of the Survey of Income and Program Participation. We do not model third and
higher-order marriages as they are very rare (Ley-Chavez 2012).

Recent tobacco use
For women’s smoking behavior, women are classified into two groups: smokers or nonsmokers. The likelihood of a non-smoker turning into a smoker is directly estimated using the
NHANES data, which also report participants’ ages at starting smoking cigarettes regularly. If a
woman becomes a smoker, she may quit smoking at any age based on an age-specific probability
of quitting smoking. We use the recent smoking cessation rate reported by the Centers for
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Disease Control and Prevention (2011) to evaluate the yearly likelihood of a smoker to quit
smoking.

Number of sex partners
The yearly changes of the number of sex partners is modeled based on the method proposed
by Ley-Chavez (2012). The number of a woman’s acquired new sex partner every year is
categorized into three groups: 0, 1, 2 and “3 or more”. Women in the category “3 or more” are
assigned 3 partners in the simulation. In this study, unmarried women include the following
status: “widowed”, “divorced”, “separated” and “never married”, while married women include
“married” and “living with partner”. The probability of unmarried women having 0 to 3 or more
new partners each year is modeled by an age-specific discrete distribution. So an unmarried
woman is randomly assigned to one of the four categories according to the discrete distribution
based on her age group. For married woman, we assume the probability of getting a new partner
in one year is 0.06 (O’Dowd 2003).

Parity
The parity in this study is defined by a binary variable indicating if a woman has had live
birth at her current age. For those who had no live birth at their current ages, they may expect a
birth in the future. The birth rates of 1st child are used to probabilistically determine when a
woman will have her first child (Martin et al. 2017). The birth rate is grouped by three factors:
age, marital status and race. As the reported birth rates of 1st child do not distinguish marital
statuses, we assume the percentage of 1st births to unmarried women (among all women) is the
same as the percentage of all births to unmarried women, which is reported to be 40.3% (Martin
et al. 2017). Then the birth rates of 1st child by age, marital status and race are estimated based
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on the three parameters: the percentages of 1st births to unmarried women, the percentage of
unmarried woman and overall birth rates of 1st child.

4.3.3 Design of Numerical Experiments
Based on the HPV risk model, two typical risk characteristics are identified using the selected
variables: a high risk woman, who has the highest HPV incidence; and a low risk woman, who
has the lowest HPV incidence (Table 6). We set multiple vaccination scenarios for the two
women, that is, the two patients are vaccinated at age 20, 26, 30, 35, 40 and 45, respectively. The
age at vaccination is also the starting age of the simulation. The simulation is run for the two
women starting from age 20 under each of the scenarios for 10,000 times. Then the average
values of the four metrics are reported for each woman under different scenarios, including life
expectancy, lifetime risk of developing cervical cancer, and lifetime risk of developing an HPVrelated cancer.

Table 6 Simulation scenarios
Candidate variable
Age at vaccination
Race
Marital status
Parity
Recent tobacco use
Age at first sex
Number of recent sex partners

High risk woman
20, 26, 30, 35, 40, 45
Black
Unmarried
Yes
Yes
<=12
>=3

Low risk woman
20, 26, 30, 35, 40, 45
Asian
Married
No
No
>=20
0

As a contrast, we also use the general female population’s HPV incidences to run the
simulation under the same 6 scenarios. The contrast demonstrates how the clinical outcomes
differ between a high risk woman, a low risk woman and an average woman. When simulating
an average woman, we do not use HPV risk model to dynamically update : H|S , but use the
age-specific incidences reported by Myers et al (2000). Table 7 summarizes the annual
incidences of HPV among the three different women. The high risk and low risk women’s
incidence rates are directly estimated using the NHANES data.
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Table 7 HPV incidences of three groups
Age at vaccination
High risk woman
Low risk woman
Average woman*
20
27.1%
4.0%
15.0%
26
24.2%
1.1%
5.0%
30
23.5%
0.4%
1.0%
35
23.4%
0.3%
1.0%
40
23.2%
0.1%
1.0%
45
23.2%
0.1%
1.0%
* Average woman’s annual incidences are collected from Myers et al. (2000)
4.3.4 Results of Numerical Experiments
Since the incidences of the HPV-related cancer among teenagers are very low (Howlader et al.
2013), we assume no woman has HPV-related cancer before age 20 and only consider every
woman’s HPV-related cancer from age 20 to death. The simulation outputs the average values of
the gain in life expectancy, lifetime risk of developing cervical cancer and lifetime risk of HPVrelated cancers for 10,000 runs. The gain in life expectancy is equal to the difference of life
expectancy between a woman receiving vaccines at a specific age and the same woman who will
never receive the vaccine. The lifetime risk of HPV-related cancers reflects the impact from the
HPV-infection before a woman gets vaccinated. Therefore, the later a woman receives vaccines,
the higher risk of developing HPV-related cancers she faces.
Table 8 shows the three types of clinical outcomes of vaccinations at different ages. The
clinical outcomes show dramatic differences among the women with different level of HPV risk.
The gain in life expectancy for high risk patient is over 10 times higher than that for the low risk
woman. However, no matter how high the risk is, receiving catch-up vaccines almost always
benefit women. The high risk woman has the highest gain in life expectancy when receiving
vaccines at age 20, which amounts to 64 days (0.176 year) on average. When getting vaccinated
at the same age, the average woman improves her life expectancy by 12 days (0.032), while the
low risk woman only gains 4 additional days in her life expectancy. The current HPV
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vaccination policy only recommends catch-up vaccines for women up to age 26, but we still see
significant improvements in life expectancy on women older than 26, especially the woman
bearing a high HPV risk, which suggests that catch-up vaccine after age 26 should be
deliberately considered.

Table 8 Clinical outcomes of HPV vaccination at different ages
Gain in life expectancy (in years)
Age at vaccination
High risk woman
Low risk woman
20
0.176
0.012
26
0.113
0.004
30
0.075
0.002
35
0.043
0.001
40
0.040
0.001
45
0.031
0.000

Average woman
0.032
0.019
0.015
0.014
0.012
0.011

Lifetime risk of developing cervical cancer
Age at vaccination
High risk woman
20
0.42%
26
0.76%
30
0.85%
35
0.90%
40
1.03%
45
1.10%

Low risk woman
0.00%
0.01%
0.01%
0.03%
0.03%
0.05%

Average woman
0.11%
0.23%
0.32%
0.37%
0.40%
0.45%

Lifetime risk of developing HPV-related cancer
Age at vaccination
High risk woman
Low risk woman
20
0.91%
0.01%
26
1.44%
0.02%
30
1.73%
0.02%
35
1.94%
0.06%
40
2.12%
0.06%
45
2.21%
0.09%

Average woman
0.24%
0.47%
0.65%
0.80%
0.82%
0.91%

Although the average gain in life expectancy from receiving catch-up vaccines after age 26 is
numerically modest even for the high risk individual, the potentially averted HPV-related cancer
cases can aggregate to substantial numbers on a group of women with the same risk profile. For
instance, the high risk woman vaccinated at age 30 has a lifetime risk of developing cervical
cancer equal to 0.85%. If the catch-up vaccine is delayed to age 45, the risk rises to 1.1%. The
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increased risk (i.e. 0.26%) is equivalent to a significant number of cancer cases when applying to
the population with the same high risk characteristics. For instance, assuming there are 100,000
women having the high risk profile, if we set the vaccination at age 45 as a baseline, the catch-up
vaccination at age 26 would prevent 770 more cancer cases compared with the vaccination at age
45. However, the vaccination as late as age 30 still could prevent 260 cervical cancer cases
compared with baseline age 45. In contrast, the increased risk on low risk woman is relatively
low, implying the necessity of personalizing the catch-up vaccination policy.

4.4 Discussion
This study showcases a novel vaccination evaluation framework, which combines a discreteevent simulation with a dynamically updated regression-based risk model. Specifically, we show
how to address dynamic risk factors and model these factors over every woman’s lifespan. The
modeling process involves a lot of data from a variety of sources and generates reasonable
results. The same approach may be applied to the clinical outcome evaluations on the vaccines
for other diseases such as hepatitis B.
What makes the study different from the prior studies on this topic is that the model works
at the individual level rather than the population level. We evaluate the impact of HPV vaccines
on different women and reveal that the catch-up vaccines after age 26 are still very beneficial for
women, especially for those with high HPV risk. Our study finds that the gain in life expectancy
for a high risk woman at age 45 is almost as high as that for an average woman if vaccinated at
age 20. These results prove that, from a pure health outcomes perspective, the HPV vaccination
policy should be personalized, rather than set at a one-size-fits-all cutoff age. Our results are
consistent with many previous arguments that support providing catch-up HPV vaccines to older
women (Muñoz et al. 2009, Schwarz et al. 2009, Westra et al. 2011). We also confirm that
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Australian’s HPV vaccination policy, which provides vaccines to women up to 45 years old, is
also rational for some US women.

Table 9 Main assumptions in the study
Assumptions
▪

Justifications and references

All women complete the 3-dose HPV

Chesson et al. 2008, Dunne et

vaccination and acquire full immunity against

al. 2014

HPV.
▪
▪

Vaccines provide women with lifetime immunity

Elbasha et al. 2007, Chesson et

against HPV infection.

al. 2008

A woman will never develop multiple HPV-

Tong et al. 2008

related cancers simultaneously.
▪

Women who have not married by age 50 will

Ley-Chavez 2012

never get married.
▪

We assume no woman has HPV-related cancers

Howlader et al. 2013

before age 20 and only consider every woman’s
HPV-related cancers from age 20 to death.
Our analysis also has some limitations. Firstly, due to the data scarcity, the diagnosis and
prognosis of the HPV-related cancers other than cervical cancer are not sufficiently modeled.
The simplified method may result in some inaccuracy in our final outcomes. The model can be
improved when the corresponding data are available. Secondly, we made several assumptions in
the parameters estimation (see Table 9). For instance, we assume the vaccines’ duration of
protection against HPV is lifelong. Currently, the long-term clinical trials that follow up the HPV
vaccines’ protection duration are still ongoing and only report 10 years effective duration
(Romanowski et al. 2016). Once the number is updated, the model may generate different
outcomes. In addition, we also assume that the efficacy of HPV is 100%. However, the vaccines’
efficacy range between 90% and 100% by vaccine types and number of vaccine shots (Dunne et
al. 2014).
122

In the future, a sensitivity analysis on the HPV efficacy and protection duration will be
conducted. Our study may also be extended to males and examines how men’s vaccination ages
impact their spouses or partners’ health. Moreover, our current study only considers lifethreating cancers related to HPV. In the future study, we may also incorporate HPV-related noncancer diseases (e.g. genital warts) to evaluate HPV vaccinations policy’s impact on qualityadjusted life years (QALYs). This extension will show how different types of vaccines,
especially those against HPV subtypes other than 16 and 18, impact women’s health.
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5 Conclusion
This dissertation performs an in-depth exploration of personalized decision modeling of cancers
intervention and prevention. We investigate the patient-specific prevention strategies for breast
cancer and HPV-related cancers, representative of cancers prevented by screening and
vaccination, respectively. Three popular healthcare analytics techniques, Markov models,
regression-based forecasting models, and discrete-event simulation, are further developed in the
context of personalized cancer medicine. Although widely used in quantities analyses of
healthcare, utilizing these approaches to optimize personalized cancer medicine was rarely
addressed in the previous literature. This dissertation explores multiple possibilities of
incorporating patient-specific risk into personalized cancer prevention and intervention strategies
and showcases three practical examples.
Chapter 2 presents a relatively simple method of personalizing cancer screening decisions.
Individual breast cancer risk is reflected in the transition probabilities of a Markov decision
process model to optimize biopsy referral decisions. The optimal biopsy referral policy can be
considered as a lifetime mammography schedule, which informs a patient when she should skip
the routine mammography in her lifetime. The study suggests that both screening mammography
and surveillance mammography schedules should be determined on a patient-specific basis.
Chapter 3 differs from chapter 2 by providing an “on-line” screening policy adaptive to a
woman’s health status. Whether a woman should receive a mammogram is determined according
to her risk level in the current year. This study emphasizes the risk model of breast cancer and
makes decisions based on the tradeoff of type I errors and type II errors. While most previous
studies optimized the breast cancer screening policy by providing lifetime mammography
screening schedules, our proposed model provides the dynamic decision model updated with
women’s latest cancer risk.
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Chapter 4 shift focus from personalized screening decisions to personalized vaccination
strategy. This study does not provide optimal decisions but rather evaluates different vaccination
scenarios’ outcomes. We demonstrate a hybrid framework combining regression-based risk
estimation with discrete-event simulation. This study discusses how to overcome the difficulty of
modeling dynamic risk factors, which are excluded in Chapter 2 and Chapter 3.
Our findings suggest that, by receiving personalized screening and vaccination, patients are
expected to have longer life expectancy and less possibility of dying from cancer. We also
provide three practical solutions for patient-specific screening and vaccination strategies.
Preventive screening and vaccination programs for other cancers or diseases, which have clearly
identified risk factors and measurable risk, may all benefit from patient-specific policies.
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